sorafenib has been researched along with Acute Myelogenous Leukemia in 203 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 11 (5.42) | 29.6817 |
| 2010's | 140 (68.97) | 24.3611 |
| 2020's | 52 (25.62) | 2.80 |
| Authors | Studies |
|---|---|
| Armstrong, RC; Belli, B; Bhagwat, SS; Brigham, D; Chao, Q; Cramer, MD; Gardner, MF; Gunawardane, RN; James, J; Karaman, MW; Levis, M; Pallares, G; Patel, HK; Pratz, KW; Sprankle, KG; Zarrinkar, PP | 1 |
| Chen, X; Cheng, C; Feng, S; Li, GB; Li, LL; Ma, S; Sun, QZ; Wang, LJ; Yang, LL; Yang, SY; Zhou, S; Zou, C | 1 |
| Chao, YS; Chen, CH; Chen, CP; Chen, CT; Chiu, CH; Chou, LH; Hsieh, SY; Hsu, JT; Hsu, T; Jiaang, WT; Lin, WH; Lu, CT; Song, JS; Tseng, YJ; Yang, YN; Yeh, CF; Yeh, TK; Yen, KJ; Yen, SC | 1 |
| Aiche, S; Bassermann, F; Becker, W; Canevari, G; Casale, E; Depaolini, SR; Ehrlich, HC; Felder, ER; Feuchtinger, A; Garz, AK; Gohlke, BO; Götze, K; Greif, PA; Hahne, H; Heinzlmeir, S; Helm, D; Huenges, J; Jeremias, I; Kayser, G; Klaeger, S; Koch, H; Koenig, PA; Kramer, K; Kuster, B; Médard, G; Meng, C; Petzoldt, S; Polzer, H; Preissner, R; Qiao, H; Reinecke, M; Reiter, K; Rueckert, L; Ruland, J; Ruprecht, B; Schlegl, J; Schmidt, T; Schneider, S; Schoof, M; Spiekermann, K; Tõnisson, N; Vick, B; Vooder, T; Walch, A; Wilhelm, M; Wu, Z; Zecha, J; Zolg, DP | 1 |
| Chen, Y; Guo, H; Jin, J; Jin, Q; Li, B; Li, T; Lin, G; Ling, J; Lu, S; Lu, T; Wang, Y; Wang, Z; Yang, T; Yao, C; Yuan, H; Zhang, L; Zhi, Y | 1 |
| Chen, Y; Heng, H; Li, H; Liu, H; Lu, S; Lu, T; Ran, T; Tian, J; Wang, S; Wang, Z; Yuan, H; Zhi, Y | 1 |
| Cai, J; Chen, Y; Guo, X; Heng, H; Huang, Y; Lan, Q; Li, H; Lu, S; Lu, T; Qin, T; Wang, S; Wang, Z; Xiang, L; Zhang, L; Zhi, Y | 1 |
| Chen, LC; Hsu, KC; Huang, HL; Huang, WJ; Lien, ST; Lin, TE; Ngo, ST; Pan, SL; Sung, TY; Tseng, HJ; Wu, YW; Yen, SC | 1 |
| Bharate, JB; Frett, B; Kharbanda, A; Lakkaniga, NR; Leung, YK; Li, HY; Mcconnell, N; Shah, NP; Wang, X; Zhang, L | 1 |
| Feng, R; Li, J; Liu, H; Ning, S; Pei, L; Sun, J; Wang, T; Xing, B; Zhao, Y; Zhu, X | 1 |
| Alshehri, B; Egbuna, C; Khan, J; Onyeike, EN; Patrick-Iwuanyanwu, KC | 1 |
| Anouty, Y; Goodman, AM; Mangan, JK; Novatcheva, ED; Saunders, I | 1 |
| Heckman, CA; Kallioniemi, O; Kivioja, J; Kontro, M; Kumar, A; Malani, D; Parsons, A | 1 |
| Baker, SD; Blachly, JS; Buelow, DR; Inaba, H; Li, L; Panetta, JC; Pounds, S; Pui, CH; Ribeiro, RC; Rubnitz, JE; Shurtleff, S; van Oosterwijk, JG | 1 |
| An, Y; Hu, B; Wang, J; Wang, Z | 1 |
| Giubellino, A; Nasrollahi, E; Rashidi, A | 1 |
| Altman, JK; Chou, WC; Groß-Langenhoff, M; Hasabou, N; Hosono, N; Lee, JH; Levis, MJ; Lu, Q; Martinelli, G; Montesinos, P; Panoskaltsis, N; Perl, AE; Podoltsev, N; Recher, C; Röllig, C; Smith, CC; Strickland, S; Tiu, RV; Yokoyama, H | 1 |
| Chen, Y; Huang, C; Jiang, L; Jiang, X; Liu, Q; Wang, Q; Xu, D; Yang, Y; Yin, C; Yin, Z; Yu, G | 1 |
| Aydin, S; Brunello, L; Busca, A; Cattel, F; Dellacasa, CM; Dogliotti, I; Giaccone, L; Passera, R; Poggiu, M; Scaldaferri, M; Zallio, F | 1 |
| Chen, Y; Deng, L; Fan, Z; Huang, F; Huang, X; Li, X; Liang, X; Liu, H; Liu, Q; Luo, X; Shi, P; Sun, J; Tu, S; Wang, Y; Xu, N; Xu, X; Xu, Y; Xuan, L | 1 |
| Bae, KH; Chan, KH; Chen, Q; Her, Z; Kurisawa, M; Lai, F; Mong, J; Niibori-Nambu, A; Osato, M; Tan, MH | 1 |
| Ghosn, M; Ghosn, S; Halabi-Tawil, M; Kaikati, J; Matar, S | 1 |
| Ai, H; Chen, L; Ji, X; Mi, RH; Song, YP; Wei, XD; Yin, QS | 1 |
| Ahmed, M; Al Ashiri, L; Duan, H; Kazi, JU; Nasimian, A; Rönnstrand, L; Zhang, X | 1 |
| Huang, Z; Meng, F; Sun, Q; Wu, B; Xu, J; Yao, Q; Zhu, Z | 1 |
| Anders, NM; Civin, CI; Hoag, SW; Kagan, AB; Lapidus, R; Moses, BS; Mott, BT; Rai, G; Rudek, MA | 1 |
| Abkowitz, JL; Appelbaum, JS; Becker, PS; Cassaday, RD; Estey, EH; Garcia, KA; Ghiuzeli, MC; Halpern, AB; Hendrie, PC; Keel, SB; Oehler, VG; Orozco, JJ; Othus, M; Percival, MM; Rodríguez-Arbolí, E; Scott, BL; Walter, RB | 1 |
| Chen, Y; Chi, P; Deng, L; Fan, Z; Huang, F; Huang, X; Jiang, L; Li, X; Liang, X; Lin, R; Liu, H; Liu, Q; Luo, X; Shao, R; Shi, P; Sun, J; Tu, S; Wang, Y; Wang, Z; Xu, N; Xu, Y; Xuan, L; Yang, K; Zhang, Y | 1 |
| Alonzo, TA; Aplenc, R; Cooper, TM; Hitzler, J; Kolb, EA; Kutny, MA; Meshinchi, S; Pollard, JA; Tasian, SK | 1 |
| Daver, N; Yilmaz, M | 1 |
| Bataller, A; Borthakur, G; Bose, P; Champlin, R; Daver, N; DiNardo, CD; Ferrajoli, A; Garcia-Manero, G; Islam, R; Jabbour, E; Jain, N; Kadia, TM; Kanagal-Shamanna, R; Kantarjian, H; Konopleva, M; Marx, KR; Molica, M; Pemmaraju, N; Rausch, CR; Ravandi, F; Shpall, E; Tidwell, RS; Wang, S; Ylimaz, M | 1 |
| Anstee, NS; Bajel, A; Bilmon, IA; Cull, G; D'Rozario, J; Enjeti, AK; Fong, CY; Hahn, U; He, S; Hiwase, DK; Iland, HJ; Kennedy, GA; Latimer, M; Leadbetter, J; Levis, MJ; Loo, S; Marlton, P; Morris, K; Murphy, N; Murray, M; Ong, DM; Ramanathan, S; Rawling, T; Reynolds, J; Roberts, AW; Rowley, L; Schwarer, AP; Seymour, JF; Taper, J; Tiley, C; Ting, SB; Tiong, IS; Verner, E; Wall, M; Wei, AH; Yuen, S | 1 |
| Chen, J; Chen, Y; Deng, L; Fan, Z; Han, M; He, J; Huang, F; Jiang, L; Li, X; Liang, X; Lin, R; Liu, H; Liu, Q; Luo, X; Luo, Y; Shao, R; Shi, P; Sun, J; Tu, S; Wang, Y; Wang, Z; Xu, N; Xu, Y; Xuan, L; Yang, K; Yu, S; Zhang, X; Zhang, Y; Zhou, X | 1 |
| Di Ianni, M; Liberatore, C | 1 |
| Stone, RM | 1 |
| Lu, YJ; Ma, LM; Tian, WW; Wang, T; Wang, X | 1 |
| Baer, MR; Dezern, A; Duong, VH; Emadi, A; Gocke, C; Gojo, I; Greer, J; Jones, RJ; Karp, J; Levis, M; Pratz, KW; Rosner, G; Rudek, MA; Smith, BD; Wright, JJ; Zahurak, M | 1 |
| Au, CH; Chan, TL; Ip, HW; Kwong, YL; Lam, SSY; Lau, JSM; Lee, HKK; Leung, AYH; Leung, GMK; Li, W; Luk, TH; Ma, ESK; Ng, NKL; Tsui, SP; Yang, N; Yip, SF; Zhang, C | 1 |
| Antar, AI; Bazarbachi, A; Jabbour, E; Mohty, M; Otrock, ZK | 1 |
| Adamia, S; Buhrlage, SJ; Case, AE; Gokhale, PC; Gray, N; Griffin, JD; Liu, X; Meng, C; Sattler, M; Stone, R; Tiv, HL; Wang, J; Weisberg, E; Yang, J | 1 |
| Kuo, DJ; Severson, E; Wong, V; Woolbright, WC | 1 |
| Balzhanova, YB; Gribanova, EO; Parovichnikova, EN; Ryzhko, VV; Samtsova, MA; Sokolov, AN | 1 |
| Berg, T; Bethge, W; Böhm, A; Bornhäuser, M; Brandts, C; Brugger, M; Bug, G; Burchardt, A; Burchert, A; Crysandt, M; Ehninger, G; Eßeling, E; Finke, J; Fritz, LV; Götze, KS; Haferlach, T; Harnisch, S; Hoeffkes, HG; Kröger, N; Lang, F; Metzelder, SK; Michel, C; Neubauer, A; Röllig, C; Rospleszcz, S; Schade-Brittinger, C; Schleuning, M; Schmid, C; Serve, H; Stelljes, M; Strauch, K; Thiede, C; Wagner, EM; Wang, Y; Wäsch, R; Wittenberg, M; Wolf, D; Wollmer, E; Wolschke, C; Wündisch, T; Zeiser, R | 1 |
| Andreeff, M; Borthakur, G; Chen, HC; Cortes, JE; Daver, N; Huang, X; Kadia, T; Kantarjian, H; Kelly, MA; Konopleva, M; McQueen, T; Patel, KP; Ravandi, F; Wang, RY; Zeng, Z | 1 |
| Cao, L; He, J; Hu, Y; Huang, H; Lai, X; Luo, Y; Shi, J; Sun, J; Tan, Y; Wei, G; Yu, J; Zhao, Y; Zheng, W; Zhu, Y | 1 |
| Chen, Y; Deng, L; Fan, Z; Huang, F; Huang, X; Jiang, L; Li, X; Liang, X; Lin, R; Liu, H; Liu, Q; Luo, X; Shi, P; Sun, J; Tu, S; Wang, Y; Wang, Z; Xu, N; Xu, Y; Xuan, L; Yu, C; Zhou, X | 1 |
| Mohty, M | 1 |
| Romero, D | 1 |
| Albors Ferreiro, M; Alonso Vence, N; Antelo Rodríguez, B; Bao Pérez, L; Bello López, JL; Cerchione, C; Cid López, M; Díaz Arias, JÁ; Ferreiro Ferro, R; González Pérez, MS; Martinelli, G; Mosquera Orgueira, A; Mosquera Torre, A; Peleteiro Raíndo, A; Pérez Encinas, MM | 1 |
| Charlet, A; Döhner, K; Duyster, J; Endres, C; Fischer, T; Gorantla, SP; Haferlach, T; Heidel, FH; Meggendorfer, M; Rummelt, C; von Bubnoff, N | 1 |
| Bottomly, D; Damnernsawad, A; Eide, CA; Kurtz, SE; McWeeney, SK; Nechiporuk, T; Tyner, JW | 1 |
| Burchert, A | 1 |
| Assanto, GM; Barberi, W; Brescini, M; Bruzzese, A; Carmini, D; De Propris, MS; Diverio, D; Galassi, G; Iori, AP; La Rocca, U; Quattrocchi, L; Trisolini, SM | 1 |
| Cho, MK; Heo, JY; Kim, S; Kim, WI; Park, TH; Yoon, SY | 1 |
| Aulitzky, W; Baldus, CD; Berdel, WE; Bornhäuser, M; Brandts, CH; Burchert, A; Dürk, H; Ehninger, G; Einsele, H; Frickhofen, N; Geer, T; Giagounidis, A; Görner, M; Hänel, M; Hanoun, M; Herbst, R; Junghanß, C; Kaiser, U; Kiani, A; Klut, IM; Krämer, A; Kramer, M; Krause, SW; Krug, U; Kullmer, J; Kunzmann, V; Link, H; Mackensen, A; Meinhardt, A; Müller-Tidow, C; Neubauer, A; Noppeney, R; Parmentier, S; Platzbecker, U; Reichle, A; Repp, R; Röllig, C; Schäfer-Eckart, K; Schaich, M; Schetelig, J; Serve, H; Thiede, C; von Bonin, M | 1 |
| Amit, O; Avni, B; Bar-On, Y; Krayem, B; Pasvolsky, O; Peretz, G; Raanani, P; Ram, R; Rozovski, U; Shargian, L; Shimony, S; Wolach, O; Yeshurun, M; Zukerman, T | 1 |
| Duffield, A; Hu, Y; Levis, M; Li, L; Nguyen, B; Seale, T; Seo, J; Small, D; Wu, M; Zhu, R | 1 |
| Lin, LP; Liu, D; Qian, JC; Tan, RX; Yuan, DD; Zhou, BB; Zhu, WJ | 1 |
| Gafter-Gvili, A; Gurion, R; Pasvolsky, O; Raanani, P; Shargian, L; Shimony, S; Wolach, O; Yeshurun, M | 1 |
| Cai, W; Chen, X; Rong, D; Tong, X; Wang, H | 1 |
| Bao Pérez, L; Cerchione, C; Isidori, A; Marconi, G; Martinelli, G; Mosquera Orgueira, A; Mosquera Torre, A; Peleteiro Raíndo, A; Pérez Encinas, MM | 1 |
| Ahmed, SO; Aljurf, M; Antar, A; Battipaglia, G; Bazarbachi, A; Belhocine, R; Brissot, E; Dulery, R; Eder, S; El Cheikh, J; Giannotti, F; Isnard, F; Jestin, M; Lapusan, S; Legrand, O; Massoud, R; Mohty, M; Rasheed, W; Rubio, MT; Ruggeri, A; Shaheen, M; Vekhoff, A | 1 |
| Dybowski, N; Godl, K; Junghanss, C; Knuebel, G; Mueller, S; Murua Escobar, H; Roolf, C; Schaab, C; Sekora, A; Tebbe, A | 1 |
| Bruner, JK; Jones, RJ; Levis, MJ; Li, L; Ma, HS; Pratilas, CA; Pratz, KW; Qin, ACR; Rudek, MA; Small, D | 1 |
| Basara, N; Burchert, A; Ditschkowski, M; Dreger, P; Fey, MF; Finck, A; Finke, J; Giagounidis, A; Götze, K; Kobbe, G; Lübbert, M; Metzelder, SK; Meyer, RG; Neubauer, A; Pabst, T; Salih, HR; Scholl, S; Schroeder, T; Wollmer, E | 1 |
| Baker, SD; Buelow, DR; Drenberg, CD; Finkelstein, D; Inaba, H; Janke, LJ; Li, L; Pabla, N; Pounds, S; Rubnitz, JE; Shi, L; Shurtleff, SA; van Oosterwijk, JG; Vasilyeva, A; Wang, YD | 1 |
| Dworacki, G; Jaskula, E; Lange, A; Lange, J; Mordak-Domagala, M; Nowak, D; Sedzimirska, M; Simiczyjew, A | 1 |
| Andrieux, G; Antin, JH; Apostolova, P; Arnold, R; Ayuk, F; Bar, M; Baumgartner, F; Becher, B; Beelen, D; Bertz, H; Bethge, W; Bettinger, D; Blazar, BR; Bonini, C; Börries, M; Braun, L; Brummer, T; Bunjes, D; Burchert, A; Busch, H; Cahn, JY; Caligiuri, MA; Chakraverty, R; Ciceri, F; Claus, R; Dengjel, J; Ditschkowski, M; Doostkam, S; Dörfel, D; Duquesne, S; Duyster, J; Ehlert, JE; Feger, D; Finke, J; Follo, M; Gerull, S; Gill, S; Haag, J; Hackanson, B; Häcker, G; Halbach, S; Halter, J; Hanke, K; Hemmati, P; Henden, AS; Herr, W; Hilgendorf, I; Hill, GR; Hochhaus, A; Holtick, U; Hu, Z; Ihorst, G; Illert, AL; Jilg, C; Kennedy, GA; Kim, DDH; Klaeger, S; Kobbe, G; Kondo, T; Kröger, N; Kuball, J; Kuchenbauer, F; Kuster, B; Labopin, M; Leiber, C; Lengerke, C; Lübbert, M; Mackensen, A; Magenau, J; Mathew, NR; McLornan, D; Meckel, S; Melchinger, W; Metzelder, SK; Mufti, G; Müller, AM; Müller, LP; Müller, TA; Nagler, A; Negrin, RS; Neubauer, A; O'Sullivan, D; Oran, B; Ordemann, R; Osswald, L; Pabst, T; Pearce, E; Pfeifer, D; Prinz, M; Reddy, P; Rezvani, K; Richardson, S; Rösler, W; Ruggiero, E; Rummelt, C; Sarma, A; Scheid, C; Schmid, C; Schmidts, A; Schmitt-Graeff, A; Schnell, J; Schroeder, T; Schultheiss, M; Shah, O; Sicre-de-Fontbrune, F; Socié, G; Spath, S; Spyridonidis, A; Stabla, K; Stölzel, F; Tanriver, Y; Taromi, S; Teshima, T; Thimme, R; Thomas, S; Tugues, S; Ullrich, E; Vago, L; van der Velden, W; von Bubnoff, N; Vuong, GL; Wagner, EM; Wäsch, R; Waterhouse, M; Weber, A; Weisdorf, D; Wilhelm, K; Wolf, D; Yan, KL; Zeiser, R | 1 |
| Deng, L; Fan, Z; Han, M; Huang, F; Huang, X; Jiang, E; Liang, X; Lin, R; Liu, Q; Sun, J; Wang, Y; Wu, B; Xu, N; Xuan, L; Ye, J; Yin, C; Zhang, Y | 1 |
| Gao, C; Gu, Z; Huang, W; Liu, Z; Wang, L; Wang, S; Yang, N | 1 |
| Fan, ZP; Huang, F; Liu, QF; Sun, J; Wang, ZX; Xu, N; Xuan, L; Ye, JY; Zhang, Y; Zhou, X | 1 |
| Andreeff, M; Borthakur, G; Burger, J; Cortes, J; Daver, N; Estrov, Z; Garcia-Manero, G; Jabbour, E; Kadia, T; Kantarjian, H; Levis, M; Ohanian, M; Patel, K; Pierce, S; Ravandi, F; Richie, MA | 1 |
| Andersson, BS; Champlin, RE; Li, Y; Liu, Y; Murray, D; Popat, U; Tang, X; Valdez, BC | 1 |
| Gerull, S; Halter, JP; Mathew, R; Nair, G; Passweg, JR; Tschan-Plessl, A | 1 |
| Higashime, A; Ichikawa, H; Kakiuchi, S; Kawaguchi, K; Kiyota, N; Kurata, K; Matsuoka, H; Minami, H; Nagao, S; Rikitake, J; Sakai, R; Yakushijin, K | 1 |
| Freyer, CW; Mangan, JK | 1 |
| Arain, S; Balanescu, DV; Donisan, T; Gould, KL; Hassan, S; Iliescu, C; Karimzad, K; Kim, P; Lopez-Mattei, J; Palaskas, N; Sudasena, D | 1 |
| Abu Zaid, M; Boswell, HS; Cripe, LD; Konig, H; Saliba, AN; Sayar, H | 1 |
| Arcese, W; Battipaglia, G; Bazarbachi, A; Blaise, D; Chantepie, S; Chevallier, P; Cornelissen, JJ; Djabali, A; El Cheikh, J; Esteve, J; Forcade, E; Hashaishi, K; Labopin, M; Medinger, M; Mohty, M; Nagler, A; Orvain, C; Passweg, J; Socié, G | 1 |
| Bixby, D; Braun, T; Brisson, J; Chappell, G; Choi, SW; Churay, T; Frame, D; Gatza, E; Geer, M; Magenau, J; Marini, B; Parkin, B; Perissinotti, A; Reddy, P | 1 |
| Chen, J; Deng, L; Fan, Z; Gao, L; Han, M; Huang, F; Huang, X; Jiang, E; Liang, X; Liu, Q; Sun, J; Tang, X; Wang, Y; Wu, B; Wu, D; Xuan, L; Zhang, X | 1 |
| Ahmed, SO; Aljurf, M; Battipaglia, G; Bazarbachi, A; El Cheikh, J; Legrand, O; Massoud, R; Mohty, M; Youniss, R | 1 |
| Alonzo, T; Aplenc, R; Barakat, LP; Gerbing, R; Johnston, DL; Kolb, EA; Meshinchi, S; Nagarajan, R; Sung, L | 1 |
| Abou Dalle, I; Andreeff, M; Borthakur, G; Bose, P; Cortes, J; Daver, N; DiNardo, C; Garcia-Manero, G; Kadia, T; Kantarjian, H; Konopleva, M; Loghavi, S; Naqvi, K; Nogueras González, GM; Patel, K; Pemmaraju, N; Pierce, S; Ravandi, F; Sasaki, K; Short, NJ; Yalniz, F; Yilmaz, M | 1 |
| Perl, AE | 1 |
| Damon, LE; Lasater, EA; Lin, KC; Salerno, S; Shah, NP; Smith, CC; Stewart, WK; Zhu, X | 1 |
| Alattar, ML; Andreeff, M; Borthakur, G; Burger, J; Cortes, J; Daver, N; Dellasala, S; Faderl, S; Garcia-Manero, G; Grunwald, MR; Kadia, T; Kantarjian, H; Konopleva, M; Levis, M; Nazha, A; Pierce, S; Rajkhowa, T; Ravandi, F; Richie, MA; Rudek, MA | 1 |
| Chandran, P; Gupta, N; Keechilat, P; Koyakutty, M; Malarvizhi, GL; Nair, S; Retnakumari, AP | 1 |
| Fischer, T; Heidel, FH; Jentsch-Ullrich, K; Krogel, C; Luehr, H; Schalk, E; Schnoeder, TM; Wolleschak, D | 1 |
| Aulitzky, W; Berdel, WE; Blau, I; Brandts, C; Brunnberg, U; Duyster, J; Ehninger, G; Fischer, T; Giagounidis, A; Heinecke, A; Krämer, A; Kreuzer, KA; Krug, U; Kunzmann, V; Müller-Tidow, C; Neubauer, A; Noppeney, R; Ottmann, O; Reichle, A; Sauerland, MC; Schaich, M; Serve, H; Steffen, B; Stuhlmann, R; Thiede, C; Wagner, R; Wandt, H | 1 |
| Baker, SD; Buaboonnam, J; Enemark, EJ; Inaba, H; Mullighan, CG; Neale, GA; Olsen, SR; Orwick, S; Rubnitz, JE; Shurtleff, S; Wang, YD; Zatechka, DS; Zimmerman, EI | 1 |
| Feng, FE; Jiang, ZH; Lin, XQ; Lu, J | 1 |
| Aplenc, R; Caparas, M; Cullen, P; Johnston, DL; Nagarajan, R; Schulte, F; Sung, L | 1 |
| Baker, SD; Buaboonnam, J; Hu, S; Inaba, H; Janke, LJ; Orwick, S; Ramachandran, A; Roberts, MS; Stewart, CF; Turner, DC; Zimmerman, EI | 1 |
| Azzarà, A; Benedetti, E; Buda, G; Caracciolo, F; Carulli, G; Fontanelli, G; Galimberti, S; Orciuolo, E; Petrini, M; Rocco, M | 1 |
| Hu, B; Mohty, M; Savani, BN; Vikas, P | 1 |
| Andreeff, M; Arana Yi, C; Borthakur, G; Brandt, M; Cortes, JE; Estrov, Z; Faderl, S; Garcia-Manero, G; Jabbour, E; Kantarjian, H; Konopleva, M; Levis, M; Luthra, R; O'Brien, S; Pierce, S; Pratz, K; Ravandi, F; Thomas, D | 1 |
| Alba, G; Carlson, T; Chen, A; Coberly, S; Dai, K; Eksterowicz, J; Hollenback, D; Huard, J; Kamb, A; Keegan, K; Li, C; Li, Z; Liang, L; Liu, L; Lo, MC; Ma, J; McGee, LR; Medina, J; Ngo, R; Orf, J; Quéva, C; Ragains, M; Wang, X; Weidner, M; Wickramasinghe, D; Zhao, S | 1 |
| Chow, HC; Gill, H; Kwong, YL; Lam, SS; Leung, AY; Man, CH; Sun, MK | 1 |
| Andreeff, M; Borthakur, G; Chen, Y; Cortes, JE; Gao, C; Jacamo, RO; Konopleva, M; Ramachandran, A; Ravandi, F; Zhang, W | 1 |
| Delabesse, E; Guenounou, S; Récher, C | 1 |
| Alvarado, Y; Andreeff, M; Borthakur, G; Cortes, JE; Estrov, Z; Garcia-Manero, G; Kantarjian, HM; Konopleva, M; Luthra, R; Ravandi, F | 1 |
| Andreeff, M; Cortes, J; Kantarjian, H; Pemmaraju, N; Ravandi, F | 1 |
| Emadi, A; Karp, JE; Pratz, KW; Sammons, SL; Smith, BD | 1 |
| Courville, E; Liegel, J; Sachs, Z; Ustun, C | 1 |
| Bernardo, L; Borger, DR; Chen, YB; Durazzo, T; Fathi, AT; Kroshinsky, D; Lin, WM; McAfee, SL; Piris, A; Sadrzadeh, H | 1 |
| Bavishi, K; Bazargan, A; Black, J; Cummins, KD; D'Rozario, J; Filshie, R; Hertzberg, M; Jane, SM; Lane, S; Nikovic, S; Ninkovic, S; Ritchie, D; Scott, A; Sutrave, G; Wei, A; Yannakou, CK | 1 |
| Andersson, BS; Champlin, RE; Li, Y; Liu, Y; Song, G; Valdez, BC | 1 |
| Antin, JH; Ballen, K; Chen, YB; Connolly, C; Curtis, M; Cutler, C; Del Rio, C; Dey, BR; El-Jawahri, A; Fathi, AT; Ho, VT; Joyce, A; Lane, AA; Levis, M; Li, S; McAfee, S; Rajkhowa, T; Rudek, M; Soiffer, R; Spitzer, TR; Valles, B; Verselis, S | 1 |
| D'Argenio, DZ; Hsu, CP; Huard, J; Kuchimanchi, M; Lu, JF; Ma, J; Sun, YN; Weidner, M; Xu, G; Xu, Y; Zhang, Y | 1 |
| Galanis, A; Levis, M | 1 |
| Antar, A; Bazarbachi, A; Kharfan-Dabaja, MA; Mahfouz, R | 1 |
| Adlard, K; Chang, B; Cooper, T; Estey, E; Garee, A; Gross, T; Gupta, S; Ho, PA; McGoldrick, S; Meshinchi, S; Neudorf, S; Pollard, JA; Sisler, I; Tarlock, K; Templeman, T; Thomson, B; Watt, T; Woolfrey, A | 1 |
| Brendel, C; Burchert, A; Fouladi, F; Henkenius, K; Hub, F; Jehn, LB; Metzelder, SK; Neubauer, A; Stiewe, T | 1 |
| Choi, WW; Chow, HC; Gill, H; Ip, AH; Kwong, YL; Leung, AY; Man, CH | 1 |
| Ai, H; Han, L; Liu, S; Mi, R; Song, Y; Wang, P; Wei, X; Yin, Q; Zhang, Y; Zhao, H | 1 |
| Aydınok, Y; Balkan, C; Karadaş, N; Kavaklı, K; Önder Siviş, Z; Yılmaz Karapınar, D | 1 |
| Ai, H; Mi, R; Wang, P; Wei, X; Xu, H; Yin, Q | 1 |
| Bhatt, VR; Giri, S; Hamdeh, S; Schwarz, JK | 1 |
| Bornhäuser, M; Brendel, C; Burchert, A; Charles, J; Ellenrieder, V; Gattenlöhner, S; Hessmann, E; Inselmann, S; Metzelder, SK; Michel, C; Neubauer, A; Rehberger, M; Sohlbach, K; Solovey, M; Stiewe, T; Ten Haaf, A; von Bonin, M; Wang, Y | 1 |
| Chang, E; Foerster, S; Gondek, L; Huso, DL; Levis, M; Li, L; Lim, Y; Ma, H; Marchionni, L; Matsui, W; McGovern, K; Merchant, AA; Peacock, CD; Small, D; Smith, BD; Wang, Q; Watkins, DN | 1 |
| Gerull, S; Halter, JP; Heim, D; Medinger, M; Passweg, JR; Tschan-Plessl, A | 1 |
| Assanelli, A; Bernardi, M; Carrabba, MG; Ciceri, F; Corti, C; De Freitas, T; Lupo Stanghellini, MT; Marktel, S; Messina, C; Peccatori, J; Piemontese, S; Tresoldi, C; Vago, L | 1 |
| Ford, LA; Freyer, CW; Griffiths, EA; Muppidi, MR; Portwood, S; Thompson, JE; Wang, ES; Wetzler, M | 1 |
| Andreeff, M; Badar, T; Borthakur, G; Champlin, R; Cortes, JE; Daver, N; Garcia Manero, G; Kadia, TM; Kantarjian, HM; Konopleva, M; Luthra, R; Nogueras-Gonzalez, GM; Oran, B; Patel, K; Ravandi, F; Wierda, WG | 1 |
| Gabrilove, J; Jing, Y; Wang, R; Waxman, S; Xia, L | 1 |
| Chandra, S; Dahl, NA; McMasters, RL; Michaels, ST; O'Brien, MM | 1 |
| Chen, T; Cheng, X; Jia, Y; Jiang, T; Li, J; Liu, T; Liu, Z; Wang, F; Zeng, J; Zhang, C; Zhang, L; Zhu, H | 1 |
| Daver, N; Konopleva, M | 1 |
| Aulitzky, W; Baldus, CD; Berdel, WE; Bornhäuser, M; Brandts, CH; Burchert, A; Dürk, H; Ehninger, G; Einsele, H; Frickhofen, N; Geer, T; Giagounidis, A; Görner, M; Hänel, M; Hase, J; Heits, F; Herbst, R; Hüttmann, A; Illmer, T; Junghanß, C; Kaiser, U; Kiani, A; Klut, IM; Krämer, A; Kramer, M; Krause, SW; Krug, U; Kullmer, J; Kunzmann, V; Link, H; Mackensen, A; Müller-Tidow, C; Neubauer, A; Noppeney, R; Parmentier, S; Reichle, A; Repp, R; Röllig, C; Schäfer-Eckart, K; Schaich, M; Schetelig, J; Serve, H; Thiede, C; von Bonin, M | 1 |
| Mihaila, RG | 1 |
| Bayhan, T; Cetin, M; Gumruk, F; Isgandarova, F; Kuskonmaz, B; Tavil, B; Unal, S | 1 |
| Beck, JF; Ernst, J; Ernst, T; Gruhn, B; Rinke, J; Schäfer, V; Wittig, S | 1 |
| Borg, Å; Cordero, E; Haraldsson, K; Hemann, MT; Kabir, NN; Kazi, JU; Levander, F; Lindblad, O; Macaulay, L; Pietras, K; Puissant, A; Ramos, A; Rönnstrand, L; Stegmaier, K; Sun, J; Vallon-Christersson, J | 1 |
| Chen, GH; Fu, CC; Gu, B; Han, Y; Ma, X; Miao, M; Qiu, HY; Shen, HJ; Sun, AN; Tang, XW; Wu, DP | 1 |
| Fan, Z; Gao, Y; Huang, F; Jiang, Q; Liu, Q; Sun, J; Xu, N; Xuan, L; Zhang, Y | 1 |
| Aplan, PD; Bruner, JK; Duffield, AS; Ghiaur, G; Greenblatt, SM; Jones, RJ; Jung, E; Li, L; Ma, HS; Nguyen, B; Shirley, CM; Small, D | 1 |
| Garcia-Manero, G; Hu, Y; Huang, A; Huang, P; Ju, HQ; Liu, D; Liu, K; Wen, S; Zhan, G | 1 |
| DU, QF; Huang, YX; Liu, XS; Long, H; Wu, BY; Xu, JH; Zhu, JY | 1 |
| Chen, B; Cooper, JL; Dovey, OM; Friedrich, M; Grove, CS; Huang, Y; Lee, B; Mupo, A; Varela, I; Vassiliou, GS | 1 |
| Kong, P; Liao, J; Liu, Y; Shen, Z; Wang, X; Yi, H; Zeng, D; Zhang, X | 1 |
| Ashman, LK; Don, AS; Dun, MD; Enjeti, A; Flanagan, H; Guthridge, MA; Harrison, C; Kahl, R; Lee, EM; Lock, RB; Mashkani, B; Moore, A; Morris, J; Panicker, N; Powell, JA; Skelding, KA; Smith, AM; Thomas, D; Toop, H; Verrills, NM | 1 |
| Alyea, EP; Antin, JH; Ballen, KK; Brunner, AM; Chen, YB; Collier, K; Connolly, C; Cutler, CS; Deangelo, DJ; Dey, BR; El-Jawahri, A; Fathi, AT; Ho, VT; Koreth, J; Li, S; McAfee, SL; Nikiforow, S; Soiffer, RJ; Spitzer, TR; Stone, RM; Wadleigh, M | 1 |
| Gui, RR; Han, LJ; Hou, YJ; Song, YP; Zhang, YL; Zhao, HF; Zhou, J; Zu, YL | 1 |
| Hosoi, H; Imamura, T; Ishida, H; Kanayama, T; Kawashima-Goto, S; Miyachi, M; Nakatani, T; Osone, S; Sugimoto, A; Takai, A; Tamura, S; Tsuma, Y | 1 |
| Au, CH; Chan, TL; Cher, CY; Cheung, AM; Gill, H; He, BL; Ho, DN; Ho, ES; Ip, HW; Kwong, YL; Lam, SS; Leung, AY; Liang, R; Ma, ES; Man, CH; Ng, NK; So, CC; So, CW; Tamburini, J; Wong, WW | 1 |
| Han, XY; Hu, J; Huang, H; Huang, Y; Sun, J; Ying, SW; Zheng, YL | 1 |
| Alvares, C; Chakraborty, M; Conner, C; Gosrani, D; Mahdi, AJ; Rayment, R; Rees, A; Wilson, K | 1 |
| Fleischmann, M; Hilgendorf, I; Hochhaus, A; Sayer, HG; Schmidt, V; Schnetzke, U; Scholl, S; Schrenk, KG | 1 |
| Horne, DA; Kowolik, CM; Lin, M; Overman, LE; Xie, J | 1 |
| Dienst, A; Germing, U; Haas, R; Heyn, C; Kobbe, G; Kondakci, M; Nachtkamp, K; Rautenberg, C; Schmidt, PV; Schroeder, T | 1 |
| Blaise, D; Charbonnier, A; D'Incan, E; Mohty, B; Rey, J; Sid, S; Vey, N | 1 |
| Bruns, I; Czibere, A; Dienst, A; Fenk, R; Haas, R; Kobbe, G; Reinecke, P; Safaian, NN | 1 |
| Andreef, M; Cortes, J; Kantarjian, H; Mori, S; Ravandi, F; Zhang, W | 1 |
| Lee, SH; Paietta, E; Racevskis, J; Wiernik, PH | 1 |
| Levis, M; Murphy, KM; Pratz, KW; Rajkhowa, T; Sato, T; Stine, A | 1 |
| Büchner, T; Krug, U; Lübbert, M | 1 |
| Andreeff, M; Bekele, BN; Borthakur, G; Brandt, M; Byrd, A; Cortes, JE; Estrov, Z; Faderl, S; Garcia-Manero, G; Jones, D; Kantarjian, HM; Konopleva, MY; Levis, M; Luthra, R; O'Brien, S; Pierce, SR; Pratz, K; Ravandi, F; Thomas, D | 1 |
| Fesler, MJ; Petruska, PJ; Richart, JM | 1 |
| Baker, SD; Carducci, MA; Cho, E; Gore, SD; Karp, JE; Levis, MJ; McDevitt, M; Pratz, KW; Rudek, MA; Smith, BD; Stine, A; Wright, JJ; Zhao, M | 1 |
| Kallert, S; Mackensen, A; Meidenbauer, N; Rech, D; Rech, J; Roesler, W; Winkler, J | 1 |
| Fricke, HJ; Hochhaus, A; Klink, A; Muegge, LO; Scholl, S; Spies-Weisshart, B | 1 |
| Burchert, A; Metzelder, SK; Neubauer, A; Wollmer, E | 1 |
| Gu, Y; Meng, F; Qu, B; Shen, Y; Shu, Y; Sun, Y; Wu, X; Xu, Q; Zhang, T; Zhao, W; Zhu, X | 1 |
| Bruns, I; Czibere, A; Fenk, R; Haas, R; Kobbe, G; Safaian, NN; Saure, C; Schroeder, T; Zohren, F | 1 |
| Andreeff, M; Borthakur, G; Cortes, JE; Faderl, S; Kantarjian, H; Konopleva, M; Mathews, S; Ravandi, F; Verstovsek, S; Wright, JJ; Zhang, W | 1 |
| Ausoni, G; Bayer, AJ; Bellesi, S; Chiusolo, P; Giammarco, S; Laurenti, L; Leone, G; Mario, B; Metafuni, E; Sica, S; Sorà, F; Zini, G | 1 |
| Fesler, MJ | 1 |
| Burnett, A; Galkin, S; Knapper, S; Levis, M; Sato, T; Small, D; Smith, BD; White, P; Yang, X | 1 |
| Amri, A; Arguello, M; Borden, K; Cormack, G; Kraljacic, BC | 1 |
| Baker, SD; Calabrese, C; Campana, D; Fan, Y; Hu, S; Inaba, H; Niu, H; Orwick, S; Panetta, JC; Pounds, S; Rehg, JE; Rose, C; Rubnitz, JE; Yang, S | 1 |
| Shen, YF; Zhang, SJ; Zhou, XJ | 1 |
| Bechelli, J; Ifthikharuddin, JJ; Jordan, CT; Liesveld, JL; Lu, C; Messina, P; Mulford, D; Phillips Ii, GL; Rosell, KE | 1 |
| Andreeff, M; Bashir, Q; Bayraktar, UD; Champlin, RE; Chen, J; Chiattone, A; Cortes, J; de Lima, M; Giralt, S; Kantarjian, H; Kebriaei, P; Konopleva, M; McCue, D; Qazilbash, M; Ravandi, F; Sharma, M | 1 |
| Baker, SD; Campana, D; Christensen, R; Coustan-Smith, E; Furmanski, BD; Heym, KM; Inaba, H; Li, L; Mascara, GP; Onciu, M; Pounds, SB; Pui, CH; Ribeiro, RC; Rubnitz, JE; Shurtleff, SA | 1 |
| Abril, C; Al-Kali, A; Brandt, M; Cortes, J; Faderl, S; Jones, D; Kantarjian, H; Pierce, S; Ravandi, F | 1 |
| Bellesi, S; Chiusolo, P; Giammarco, S; Laurenti, L; Leone, G; Metafuni, E; Sica, S; Sorà, F; Za, T | 1 |
| How, GF; Linn, YC; Loh, Y; Mohan, BP | 1 |
| Cooper, T; Watt, TC | 1 |
| Berdel, WE; Brandts, C; Ehninger, G; Haibach, M; Hentrich, M; Junghanß, C; Krämer, A; Kramer, M; Krause, SW; Müller-Tidow, C; Pflüger, KH; Ritter, B; Röllig, C; Schleyer, E; Serve, H; Shaid, S | 1 |
| Celeghini, C; Melloni, E; Norcio, A; Secchiero, P; Voltan, R; Zauli, G | 1 |
| Atrash, B; Avery, S; Bavetsias, V; Blagg, J; de Haven Brandon, A; Eccles, SA; Faisal, A; Gonzalez de Castro, D; Linardopoulos, S; Mair, D; Mirabella, F; Moore, AS; Pearson, AD; Raynaud, FI; Sun, C; Swansbury, J; Valenti, M; Workman, P | 1 |
| Cheung, AM; Choi, WW; Chow, HC; Eaves, C; Fung, TK; Han, HH; Ho, C; Kwong, YL; Leung, AY; Lok, S; Ma, AC; Man, CH | 1 |
| Abrams, SL; Andreeff, M; Bergamo, P; Chiaretti, S; Ciuffreda, L; Cognetti, F; Del Bufalo, D; Foà, R; Konopleva, M; Marchetti, A; Mascolo, MG; McCubrey, JA; Milella, M; Petrucci, MT; Ricciardi, MR; Scerpa, MC; Steelman, LS; Tafuri, A; Tavolaro, S; Tsao, T | 1 |
| Baldus, C; Basara, N; Brugger, W; Burchert, A; Dreger, P; Fey, M; Finck, A; Giagounidis, A; Götze, K; Heinicke, T; Kröger, M; Linn, YC; Metzelder, SK; Meyer, RG; Mori, M; Müller, L; Neubauer, A; Reiter, A; Salih, HR; Schäfer-Eckart, K; Scholl, S; Schroeder, T; Schultheis, B; Stuhlmann, R; Vöhringer, M | 1 |
| Cortes, J; Daver, N | 1 |
| Freeman, C; Giles, F; Swords, R | 1 |
| Ayala, R; Canal, A; Castro, N; Grande, C; Martínez-López, J; Rueda, D | 1 |
| Celeghini, C; di Iasio, MG; Lanza, F; Melloni, E; Ongari, M; Secchiero, P; Tiribelli, M; Voltan, R; Zauli, G | 1 |
| Secchiero, P; Tisato, V; Voltan, R; Zauli, G | 1 |
| Tan, P; Wei, A | 1 |
| Andreeff, M; Borthakur, G; Jin, L; Kantarjian, H; Konopleva, M; Lu, H; Miida, T; Tabe, Y | 1 |
| Assouline, SE; Brandwein, J; Caplan, S; Couban, S; Eisenhauer, EA; Foo, A; Kamel-Reid, S; Leber, B; Macdonald, DA; Walsh, W | 1 |
| Sattler, M; Weisberg, E | 1 |
| Al-Riyami, AZ; Forrest, D; Hudoba, M; Young, S | 1 |
| Chow, S; Hedley, D; Tong, FK | 1 |
| Duyster, J; Grundler, R; Kancha, RK; Peschel, C | 1 |
| Andreeff, M; Bornmann, WG; Cortes, J; Evans, RL; Konopleva, M; McCubrey, J; McQueen, T; Ruvolo, VR; Zhang, W | 1 |
| Andreeff, M; Cortes, J; Estrov, Z; Harris, D; Konopleva, M; Ling, X; McQueen, T; Quintás-Cardama, A; Shi, YX; Small, D; Zhang, W | 1 |
| Ehninger, G; Illmer, T | 1 |
| Chow, S; Goolsby, C; Hedley, DW; Shankey, TV | 1 |
| Baker, SD; Dahl, GV; Hu, S; Inaba, H; Minkin, P; Niu, H; Orwick, S; Rubnitz, J; Shimada, A | 1 |
21 review(s) available for sorafenib and Acute Myelogenous Leukemia
| Article | Year |
|---|---|
FMS-Like Tyrosine Kinase 3 Inhibitors for the Treatment of Acute Myeloid Leukemia.
Topics: Antineoplastic Agents; fms-Like Tyrosine Kinase 3; Humans; Leukemia, Myeloid, Acute; Mutation; Protein Kinase Inhibitors; Sorafenib | 2022 |
Novel Approaches to Treatment of Acute Myeloid Leukemia Relapse Post Allogeneic Stem Cell Transplantation.
Topics: Hematopoietic Stem Cell Transplantation; Humans; Leukemia, Myeloid, Acute; Protein Kinase Inhibitors; Recurrence; Sorafenib | 2023 |
FLT3 inhibitors in acute myeloid leukemia: ten frequently asked questions.
Topics: Aniline Compounds; Antineoplastic Agents; Benzimidazoles; Benzothiazoles; Carbazoles; DNA Methylation; Enzyme Inhibitors; fms-Like Tyrosine Kinase 3; Furans; Humans; Leukemia, Myeloid, Acute; Mutation; Neoplasm Recurrence, Local; Phenylurea Compounds; Piperidines; Prognosis; Pyrazines; Randomized Controlled Trials as Topic; Sorafenib; Staurosporine; Treatment Outcome | 2020 |
FLT3 inhibitors in the treatment of acute myeloid leukemia: current status and future perspectives.
Topics: Aniline Compounds; Antineoplastic Agents; Benzimidazoles; Benzothiazoles; Carbazoles; Drug Resistance, Multiple; Drug Resistance, Neoplasm; fms-Like Tyrosine Kinase 3; Forecasting; Furans; Hematopoietic Stem Cell Transplantation; Humans; Imidazoles; Leukemia, Myeloid, Acute; Maintenance Chemotherapy; Mutation; Phenylurea Compounds; Piperidines; Point Mutation; Protein Kinase Inhibitors; Pyrazines; Pyridazines; Recurrence; Sorafenib; Staurosporine | 2020 |
Maintenance therapy for
Topics: fms-Like Tyrosine Kinase 3; Hematopoietic Stem Cell Transplantation; Humans; Leukemia, Myeloid, Acute; Maintenance Chemotherapy; Mutation; Protein Kinase Inhibitors; Sorafenib | 2021 |
Maintenance therapy after allogeneic hematopoietic transplant for acute myeloid leukemia: a systematic review and meta-analysis.
Topics: Hematopoietic Stem Cell Transplantation; Humans; Leukemia, Myeloid, Acute; Recurrence; Sorafenib | 2021 |
Availability of FLT3 inhibitors: how do we use them?
Topics: Aniline Compounds; Animals; Antineoplastic Agents; Benzothiazoles; Clinical Trials as Topic; fms-Like Tyrosine Kinase 3; Humans; Leukemia, Myeloid, Acute; Phenylurea Compounds; Protein Kinase Inhibitors; Pyrazines; Sorafenib; Staurosporine | 2019 |
Rapid induction of complete molecular remission by sequential therapy with LDAC and sorafenib in FLT3-ITD-positive patients unfit for intensive treatment: two cases and review of the literature.
Topics: Aged; Antibody Specificity; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Female; fms-Like Tyrosine Kinase 3; Humans; Leukemia, Myeloid, Acute; Lymphocytes; Middle Aged; Niacinamide; Phenylurea Compounds; Prognosis; Remission Induction; Sorafenib | 2013 |
Allogeneic stem cell transplantation and targeted therapy for FLT3/ITD+ acute myeloid leukemia: an update.
Topics: Carbazoles; Drug Resistance, Neoplasm; fms-Like Tyrosine Kinase 3; Furans; Hematopoietic Stem Cell Transplantation; Humans; Leukemia, Myeloid, Acute; Niacinamide; Phenylurea Compounds; Piperazines; Protein Kinase Inhibitors; Quinazolines; Sorafenib; Tandem Repeat Sequences; Transplantation, Homologous | 2014 |
Investigational FMS-like tyrosine kinase 3 inhibitors in treatment of acute myeloid leukemia.
Topics: Animals; Antineoplastic Agents; Benzimidazoles; Benzothiazoles; Drug Resistance, Neoplasm; fms-Like Tyrosine Kinase 3; Humans; Imidazoles; Leukemia, Myeloid, Acute; Niacinamide; Phenylurea Compounds; Piperidines; Protein Kinase Inhibitors; Pyridazines; Sorafenib; Staurosporine | 2014 |
[Sorafenib in combination with chemotherapy as induction therapy for FLT3-ITD positive acute myeloid leukemia:nine cases report and literatures review].
Topics: Humans; Leukemia, Myeloid, Acute; Niacinamide; Phenylurea Compounds; Sorafenib | 2015 |
Hypertension and Life-Threatening Bleeding in Children with Relapsed Acute Myeloblastic Leukemia Treated with FLT3 Inhibitors.
Topics: Acidosis; Acute Kidney Injury; Adenine Nucleotides; Antineoplastic Combined Chemotherapy Protocols; Arabinonucleosides; Child; Child, Preschool; Clofarabine; Cytarabine; Fatal Outcome; Female; fms-Like Tyrosine Kinase 3; Hemorrhage; Humans; Hypertension; Indoles; Leukemia, Myeloid, Acute; Male; Neoplasm Proteins; Niacinamide; Pain; Pancytopenia; Phenylurea Compounds; Protease Inhibitors; Pyrroles; Salvage Therapy; Sepsis; Sorafenib; Sunitinib | 2015 |
A minireview on NHE1 inhibitors. A rediscovered hope in oncohematology.
Topics: Amiloride; Antineoplastic Agents; Apoptosis; Cation Transport Proteins; Cell Line, Tumor; DNA Damage; Drug Interactions; fms-Like Tyrosine Kinase 3; Genes, abl; Guanidines; Heme Oxygenase-1; Humans; Hydrogen-Ion Concentration; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Leukemia, Myeloid, Acute; Mutation; Niacinamide; Osmolar Concentration; Patents as Topic; Phenylurea Compounds; Protein Kinase Inhibitors; Signal Transduction; Sodium-Hydrogen Exchanger 1; Sodium-Hydrogen Exchangers; Sorafenib; Sulfones; Tumor Hypoxia; Up-Regulation | 2015 |
Potential role of sorafenib in the treatment of acute myeloid leukemia.
Topics: Benzenesulfonates; Drug Delivery Systems; Humans; Leukemia, Myeloid, Acute; Niacinamide; Phenylurea Compounds; Pyridines; Signal Transduction; Sorafenib | 2008 |
Maintenance therapy in acute myeloid leukemia revisited: will new agents rekindle an old interest?
Topics: Azacitidine; Benzenesulfonates; Decitabine; Enzyme Inhibitors; Humans; Leukemia, Myeloid, Acute; Niacinamide; Phenylurea Compounds; Prenylation; Protein-Tyrosine Kinases; Pyridines; Sorafenib; Staurosporine | 2010 |
[Progression of sorafenib in the treatment of acute myeloid leukemia].
Topics: Antineoplastic Agents; Benzenesulfonates; Humans; Leukemia, Myeloid, Acute; Niacinamide; Phenylurea Compounds; Pyridines; Sorafenib | 2011 |
Molecular targeted therapy in acute myeloid leukemia.
Topics: Animals; Antineoplastic Agents; Benzenesulfonates; Benzothiazoles; fms-Like Tyrosine Kinase 3; Humans; Janus Kinase 2; Leukemia, Myeloid, Acute; Molecular Targeted Therapy; Mutation; Niacinamide; Phenylurea Compounds; Pyridines; ras Proteins; Sorafenib; Staurosporine | 2012 |
Targeting the FMS-like tyrosine kinase 3 in acute myeloid leukemia.
Topics: Benzenesulfonates; Benzothiazoles; Carbazoles; CCAAT-Enhancer-Binding Protein-alpha; fms-Like Tyrosine Kinase 3; Furans; Humans; Leukemia, Myeloid, Acute; Mutation; Niacinamide; Phenylurea Compounds; Prognosis; Pyridines; Sorafenib; Staurosporine | 2012 |
State of the art of the therapeutic perspective of sorafenib against hematological malignancies.
Topics: Apoptosis; Clinical Trials as Topic; fms-Like Tyrosine Kinase 3; Hematologic Neoplasms; Humans; Leukemia, Myeloid, Acute; Myeloid Cell Leukemia Sequence 1 Protein; Niacinamide; Phenylurea Compounds; Proto-Oncogene Proteins c-bcl-2; Proto-Oncogene Proteins c-mdm2; Receptors, Vascular Endothelial Growth Factor; Sorafenib; TNF-Related Apoptosis-Inducing Ligand | 2012 |
FLT3 kinase inhibitors in the management of acute myeloid leukemia.
Topics: Benzenesulfonates; Carbazoles; Clinical Trials as Topic; fms-Like Tyrosine Kinase 3; Furans; Humans; Indoles; Leukemia, Myeloid, Acute; Niacinamide; Phenylurea Compounds; Piperazines; Protein Kinase Inhibitors; Pyridines; Pyrroles; Quinazolines; Sorafenib; Staurosporine; Sunitinib | 2007 |
Pharmacodynamic monitoring of molecular-targeted agents in the peripheral blood of leukemia patients using flow cytometry.
Topics: Antineoplastic Agents; Benzenesulfonates; Clinical Trials, Phase I as Topic; Drug Monitoring; Flow Cytometry; Gene Targeting; Humans; Leukemia, Myeloid, Acute; Niacinamide; Phenylurea Compounds; Pyridines; Sorafenib | 2008 |
31 trial(s) available for sorafenib and Acute Myelogenous Leukemia
| Article | Year |
|---|---|
Effect of sorafenib maintenance on Epstein-Barr virus and cytomegalovirus infections in patients with FLT3-ITD AML undergoing allogeneic hematopoietic stem cell transplantation: a secondary analysis of a randomized clinical trial.
Topics: Cytomegalovirus Infections; Epstein-Barr Virus Infections; fms-Like Tyrosine Kinase 3; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; Herpesvirus 4, Human; Humans; Leukemia, Myeloid, Acute; Retrospective Studies; Sorafenib | 2022 |
Phase 1/2 study of sorafenib added to cladribine, high-dose cytarabine, G-CSF, and mitoxantrone in untreated AML.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Cladribine; Cytarabine; Granulocyte Colony-Stimulating Factor; Humans; Leukemia, Myeloid, Acute; Middle Aged; Mitoxantrone; Sorafenib | 2023 |
Sorafenib maintenance after allogeneic haemopoietic stem-cell transplantation in patients with FLT3-ITD acute myeloid leukaemia: long-term follow-up of an open-label, multicentre, randomised, phase 3 trial.
Topics: Bronchiolitis Obliterans Syndrome; Disease Progression; fms-Like Tyrosine Kinase 3; Follow-Up Studies; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; Humans; Leukemia, Myeloid, Acute; Neoplasm Recurrence, Local; Sorafenib | 2023 |
Phase II study of cladribine, idarubicin, and ara-C (CLIA) with or without sorafenib as initial therapy for patients with acute myeloid leukemia.
Topics: Antineoplastic Combined Chemotherapy Protocols; Cladribine; Cytarabine; Humans; Idarubicin; Leukemia, Myeloid, Acute; Middle Aged; Remission Induction; Sorafenib | 2023 |
Sorafenib plus intensive chemotherapy in newly diagnosed FLT3-ITD AML: a randomized, placebo-controlled study by the ALLG.
Topics: fms-Like Tyrosine Kinase 3; Hematopoietic Stem Cell Transplantation; Humans; Leukemia, Myeloid, Acute; Retrospective Studies; Sorafenib | 2023 |
Sorafenib and omacetaxine mepesuccinate as a safe and effective treatment for acute myeloid leukemia carrying internal tandem duplication of Fms-like tyrosine kinase 3.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Disease Progression; Disease-Free Survival; Drug Administration Schedule; Drug Resistance, Neoplasm; Drug Synergism; Exons; Female; fms-Like Tyrosine Kinase 3; Gene Duplication; Hematopoietic Stem Cell Transplantation; Homoharringtonine; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged; Neoplasm Recurrence, Local; Nucleophosmin; Remission Induction; Sorafenib; Transplantation, Homologous; Young Adult | 2020 |
Sorafenib Maintenance After Allogeneic Hematopoietic Stem Cell Transplantation for Acute Myeloid Leukemia With
Topics: Adolescent; Adult; Aged; Antineoplastic Agents; Chemotherapy, Adjuvant; Double-Blind Method; Female; fms-Like Tyrosine Kinase 3; Germany; Hematopoietic Stem Cell Transplantation; Humans; Leukemia, Myeloid, Acute; Maintenance Chemotherapy; Male; Middle Aged; Mutation; Neoplasm, Residual; Protein Kinase Inhibitors; Recurrence; Sorafenib; Tandem Repeat Sequences; Time Factors; Transplantation, Homologous; Treatment Outcome; Young Adult | 2020 |
Phase 1 study of combinatorial sorafenib, G-CSF, and plerixafor treatment in relapsed/refractory, FLT3-ITD-mutated acute myelogenous leukemia patients.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Benzylamines; Cyclams; Disease-Free Survival; Female; fms-Like Tyrosine Kinase 3; Granulocyte Colony-Stimulating Factor; Heterocyclic Compounds; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged; Mutation; Sorafenib; Survival Rate | 2020 |
Sorafenib maintenance in patients with FLT3-ITD acute myeloid leukaemia undergoing allogeneic haematopoietic stem-cell transplantation: an open-label, multicentre, randomised phase 3 trial.
Topics: Adolescent; Adult; China; Disease-Free Survival; Drug-Related Side Effects and Adverse Reactions; Female; fms-Like Tyrosine Kinase 3; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged; Protein Kinase Inhibitors; Remission Induction; Sorafenib; Tandem Repeat Sequences; Transplantation, Homologous; Young Adult | 2020 |
Sorafenib or placebo in patients with newly diagnosed acute myeloid leukaemia: long-term follow-up of the randomized controlled SORAML trial.
Topics: Adolescent; Adult; Antineoplastic Agents; Double-Blind Method; Female; Follow-Up Studies; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged; Neoplasm Recurrence, Local; Prognosis; Sorafenib; Survival Rate; Young Adult | 2021 |
Sorafenib Combined with 5-azacytidine in Older Patients with Untreated FLT3-ITD Mutated Acute Myeloid Leukemia.
Topics: Age Factors; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Azacitidine; fms-Like Tyrosine Kinase 3; Humans; Leukemia, Myeloid, Acute; Middle Aged; Mutation; Remission Induction; Salvage Therapy; Sorafenib; Stem Cell Transplantation; Survival Analysis; Transplantation, Homologous; Treatment Outcome | 2018 |
Sorafenib Therapy Is Associated with Improved Outcomes for FMS-like Tyrosine Kinase 3 Internal Tandem Duplication Acute Myeloid Leukemia Relapsing after Allogeneic Hematopoietic Stem Cell Transplantation.
Topics: Adolescent; Adult; Allografts; Disease-Free Survival; Female; fms-Like Tyrosine Kinase 3; Hematopoietic Stem Cell Transplantation; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged; Retrospective Studies; Salvage Therapy; Sorafenib; Survival Rate; Tandem Repeat Sequences | 2019 |
Quality of life in pediatric acute myeloid leukemia: Report from the Children's Oncology Group.
Topics: Adolescent; Bortezomib; Child; Child, Preschool; Drug Therapy; Drug-Related Side Effects and Adverse Reactions; Female; Humans; Leukemia, Myeloid, Acute; Male; Quality of Life; Self Report; Sorafenib | 2019 |
Prognostic significance of baseline FLT3-ITD mutant allele level in acute myeloid leukemia treated with intensive chemotherapy with/without sorafenib.
Topics: Adolescent; Adult; Aged; Alleles; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Disease-Free Survival; Female; fms-Like Tyrosine Kinase 3; Follow-Up Studies; Humans; Idarubicin; Leukemia, Myeloid, Acute; Male; Middle Aged; Mutation; Retrospective Studies; Sorafenib; Survival Rate; Tandem Repeat Sequences | 2019 |
Phase 2 study of azacytidine plus sorafenib in patients with acute myeloid leukemia and FLT-3 internal tandem duplication mutation.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Azacitidine; Feasibility Studies; Female; fms-Like Tyrosine Kinase 3; Follow-Up Studies; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged; Mutation; Neoplasm Recurrence, Local; Niacinamide; Phenylurea Compounds; Prognosis; Remission Induction; Sorafenib; Survival Rate; Tandem Repeat Sequences; Young Adult | 2013 |
Sorafenib in combination with intensive chemotherapy in elderly patients with acute myeloid leukemia: results from a randomized, placebo-controlled trial.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Double-Blind Method; Female; fms-Like Tyrosine Kinase 3; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged; Mutation; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Sorafenib | 2013 |
Reasons for non-completion of health related quality of life evaluations in pediatric acute myeloid leukemia: a report from the Children's Oncology Group.
Topics: Adolescent; Boronic Acids; Bortezomib; Child; Child, Preschool; Female; Group Processes; Hematopoietic Stem Cell Transplantation; Humans; Leukemia, Myeloid, Acute; Male; Niacinamide; Parents; Phenylurea Compounds; Pyrazines; Quality of Life; Self Report; Sorafenib; Surveys and Questionnaires; Survival Analysis; Young Adult | 2013 |
Final report of phase II study of sorafenib, cytarabine and idarubicin for initial therapy in younger patients with acute myeloid leukemia.
Topics: Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Humans; Idarubicin; Leukemia, Myeloid, Acute; Niacinamide; Phenylurea Compounds; Sorafenib; Treatment Outcome | 2014 |
Phase I trial of maintenance sorafenib after allogeneic hematopoietic stem cell transplantation for fms-like tyrosine kinase 3 internal tandem duplication acute myeloid leukemia.
Topics: Adult; Aged; Allografts; Disease-Free Survival; Female; fms-Like Tyrosine Kinase 3; Graft vs Host Disease; Humans; Leukemia, Myeloid, Acute; Maintenance Chemotherapy; Male; Middle Aged; Mutagenesis, Insertional; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Remission Induction; Sorafenib; Survival Rate | 2014 |
Addition of sorafenib versus placebo to standard therapy in patients aged 60 years or younger with newly diagnosed acute myeloid leukaemia (SORAML): a multicentre, phase 2, randomised controlled trial.
Topics: Adult; Age Factors; Antibiotics, Antineoplastic; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Cytarabine; Daunorubicin; Disease Progression; Disease-Free Survival; Double-Blind Method; Female; Germany; Hematopoietic Stem Cell Transplantation; Humans; Kaplan-Meier Estimate; Leukemia, Myeloid, Acute; Male; Middle Aged; Neoadjuvant Therapy; Niacinamide; Phenylurea Compounds; Proportional Hazards Models; Protein Kinase Inhibitors; Recurrence; Risk Factors; Sorafenib; Time Factors; Transplantation, Homologous; Treatment Outcome | 2015 |
Homoharringtonine (omacetaxine mepesuccinate) as an adjunct for FLT3-ITD acute myeloid leukemia.
Topics: Adult; Aged; Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow; Cell Culture Techniques; Cell Line, Tumor; Cluster Analysis; Drug Evaluation, Preclinical; Drug Synergism; Female; fms-Like Tyrosine Kinase 3; Gene Duplication; Harringtonines; Homoharringtonine; Humans; Leukemia, Myeloid, Acute; Male; Mice; Middle Aged; Models, Biological; Niacinamide; Phenylurea Compounds; Protein Biosynthesis; Remission Induction; Sorafenib; Treatment Outcome; Young Adult | 2016 |
Sorafenib and azacitidine as salvage therapy for relapse of FLT3-ITD mutated AML after allo-SCT.
Topics: Adult; Allografts; Azacitidine; Disease-Free Survival; Female; fms-Like Tyrosine Kinase 3; Hematopoietic Stem Cell Transplantation; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged; Niacinamide; Phenylurea Compounds; Recurrence; Salvage Therapy; Sorafenib; Survival Rate | 2017 |
Phase I/II study of combination therapy with sorafenib, idarubicin, and cytarabine in younger patients with acute myeloid leukemia.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Benzenesulfonates; Cytarabine; Feasibility Studies; Female; fms-Like Tyrosine Kinase 3; Humans; Idarubicin; Leukemia, Myeloid, Acute; Male; Middle Aged; Mutation; Neoplasm Staging; Niacinamide; Phenylurea Compounds; Pyridines; Sorafenib; Survival Rate; Treatment Outcome; Young Adult | 2010 |
Phase I study of sorafenib in patients with refractory or relapsed acute leukemias.
Topics: Adult; Aged; Aged, 80 and over; Benzenesulfonates; Female; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Leukemia, Myeloid, Acute; Male; Middle Aged; Myelodysplastic Syndromes; Neoplasm Recurrence, Local; Niacinamide; Phenylurea Compounds; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Prognosis; Protein Kinase Inhibitors; Pyridines; Remission Induction; Salvage Therapy; Sorafenib; Survival Rate; Young Adult | 2011 |
Proteasome inhibition in myelodysplastic syndromes and acute myelogenous leukemia cell lines.
Topics: Antineoplastic Agents; Apoptosis; Arsenic Trioxide; Arsenicals; Azacitidine; Benzenesulfonates; Boronic Acids; Bortezomib; Cell Line, Tumor; Cell Proliferation; Cytarabine; Cytokines; Farnesyltranstransferase; Hematopoietic Stem Cells; Humans; Leukemia, Myeloid, Acute; Myelodysplastic Syndromes; Niacinamide; Oxides; Phenylurea Compounds; Protease Inhibitors; Proteasome Inhibitors; Pyrazines; Pyridines; Sorafenib | 2011 |
Phase I pharmacokinetic and pharmacodynamic study of the multikinase inhibitor sorafenib in combination with clofarabine and cytarabine in pediatric relapsed/refractory leukemia.
Topics: Adenine Nucleotides; Adolescent; Antineoplastic Combined Chemotherapy Protocols; Arabinonucleosides; Benzenesulfonates; Child; Clofarabine; Cytarabine; Drug Administration Schedule; Drug Resistance, Neoplasm; Female; Humans; Leukemia; Leukemia, Myeloid, Acute; Male; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Pyridines; Recurrence; Sorafenib | 2011 |
Sorafenib treatment of FLT3-ITD(+) acute myeloid leukemia: favorable initial outcome and mechanisms of subsequent nonresponsiveness associated with the emergence of a D835 mutation.
Topics: Adult; Aldehyde Dehydrogenase; Aldehyde Dehydrogenase 1 Family; Animals; Antineoplastic Agents; Benzenesulfonates; Bone Marrow; Drug Resistance, Neoplasm; Female; fms-Like Tyrosine Kinase 3; Gene Expression Profiling; Gene Expression Regulation, Leukemic; Humans; Janus Kinase 3; Leukemia, Myeloid, Acute; Male; Matrix Metalloproteinase 15; Mice; Mice, Inbred NOD; Mice, SCID; Middle Aged; Mutation; Neoplasm Transplantation; Niacinamide; Phenylurea Compounds; Protein Structure, Tertiary; Pyridines; Retinal Dehydrogenase; Sorafenib; Time Factors; Transplantation, Heterologous | 2012 |
The sorafenib plus nutlin-3 combination promotes synergistic cytotoxicity in acute myeloid leukemic cells irrespectively of FLT3 and p53 status.
Topics: Antineoplastic Agents; Drug Synergism; Female; fms-Like Tyrosine Kinase 3; HL-60 Cells; Humans; Imidazoles; Leukemia, Myeloid, Acute; Male; Niacinamide; Phenylurea Compounds; Piperazines; Sorafenib; Tumor Suppressor Protein p53 | 2012 |
A phase I/II study of sorafenib in combination with low dose cytarabine in elderly patients with acute myeloid leukemia or high-risk myelodysplastic syndrome from the National Cancer Institute of Canada Clinical Trials Group: trial IND.186.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Female; fms-Like Tyrosine Kinase 3; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged; Mutation; Myelodysplastic Syndromes; Niacinamide; Phenylurea Compounds; Sorafenib; Treatment Outcome | 2013 |
Pharmacodynamic monitoring of BAY 43-9006 (Sorafenib) in phase I clinical trials involving solid tumor and AML/MDS patients, using flow cytometry to monitor activation of the ERK pathway in peripheral blood cells.
Topics: Aged; Aged, 80 and over; Antigens, CD; Antigens, CD34; Antigens, Differentiation, Myelomonocytic; Benzenesulfonates; CD13 Antigens; CD3 Complex; Drug Monitoring; Extracellular Signal-Regulated MAP Kinases; Flow Cytometry; Hemolysis; Humans; Leukemia, Myeloid, Acute; Leukocytes, Mononuclear; MAP Kinase Signaling System; Middle Aged; Models, Biological; Myelodysplastic Syndromes; Neoplasms; Niacinamide; Phenylurea Compounds; Phosphorylation; Pyridines; Sialic Acid Binding Ig-like Lectin 3; Sorafenib; Stem Cell Factor; Stem Cells; Tetradecanoylphorbol Acetate | 2006 |
Mutant FLT3: a direct target of sorafenib in acute myelogenous leukemia.
Topics: Animals; Antineoplastic Agents; Apoptosis; Benzenesulfonates; Cell Line, Tumor; Cell Survival; Fluorescent Antibody Technique; fms-Like Tyrosine Kinase 3; Humans; Immunoblotting; Kaplan-Meier Estimate; Leukemia, Myeloid, Acute; Mice; Mice, SCID; Mutation; Neoplastic Cells, Circulating; Niacinamide; Phenylurea Compounds; Polymerase Chain Reaction; Protein Kinase Inhibitors; Pyridines; Sorafenib; Transplantation, Heterologous | 2008 |
151 other study(ies) available for sorafenib and Acute Myelogenous Leukemia
| Article | Year |
|---|---|
AC220 is a uniquely potent and selective inhibitor of FLT3 for the treatment of acute myeloid leukemia (AML).
Topics: Animals; Benzenesulfonates; Benzothiazoles; Bone Marrow; Carbazoles; Cell Line, Tumor; Cell Proliferation; Female; fms-Like Tyrosine Kinase 3; Furans; Humans; Leukemia, Myeloid, Acute; Mice; Mice, Nude; Mice, SCID; Niacinamide; Phenylurea Compounds; Phosphorylation; Piperazines; Prognosis; Protein Interaction Mapping; Protein Kinase C; Protein Kinase Inhibitors; Pyridines; Quinazolines; Sorafenib; Staurosporine; Xenograft Model Antitumor Assays | 2009 |
Structure-activity relationship studies of pyrazolo[3,4-d]pyrimidine derivatives leading to the discovery of a novel multikinase inhibitor that potently inhibits FLT3 and VEGFR2 and evaluation of its activity against acute myeloid leukemia in vitro and in
Topics: Angiogenesis Inhibitors; Animals; Animals, Genetically Modified; Antineoplastic Agents; Apoptosis; Cell Line, Tumor; Cell Proliferation; Drug Screening Assays, Antitumor; Embryo, Nonmammalian; fms-Like Tyrosine Kinase 3; Humans; Leukemia, Myeloid, Acute; Mice; Neoplasm Transplantation; Phenylurea Compounds; Pyrazoles; Pyrimidines; Signal Transduction; Structure-Activity Relationship; Transplantation, Heterologous; Urea; Vascular Endothelial Growth Factor Receptor-2; Zebrafish | 2013 |
Discovery of 3-phenyl-1H-5-pyrazolylamine derivatives containing a urea pharmacophore as potent and efficacious inhibitors of FMS-like tyrosine kinase-3 (FLT3).
Topics: Animals; Antineoplastic Agents; Benzamides; Cell Line, Tumor; Cell Proliferation; Drug Discovery; fms-Like Tyrosine Kinase 3; Humans; Inhibitory Concentration 50; Leukemia, Myeloid, Acute; Mice; Protein Kinase Inhibitors; Sensitivity and Specificity; Structure-Activity Relationship; Urea; Xenograft Model Antitumor Assays | 2013 |
The target landscape of clinical kinase drugs.
Topics: Animals; Antineoplastic Agents; Cell Line, Tumor; Cytokines; Drug Discovery; fms-Like Tyrosine Kinase 3; Humans; Leukemia, Myeloid, Acute; Lung Neoplasms; Mice; Molecular Targeted Therapy; Protein Kinase Inhibitors; Protein Serine-Threonine Kinases; Proteomics; Xenograft Model Antitumor Assays | 2017 |
Discovery of 4-((7H-Pyrrolo[2,3-d]pyrimidin-4-yl)amino)-N-(4-((4-methylpiperazin-1-yl)methyl)phenyl)-1H-pyrazole-3-carboxamide (FN-1501), an FLT3- and CDK-Kinase Inhibitor with Potentially High Efficiency against Acute Myelocytic Leukemia.
Topics: Amides; Animals; Antineoplastic Agents; Cell Line, Tumor; Cyclin-Dependent Kinases; Drug Discovery; fms-Like Tyrosine Kinase 3; Heterografts; Humans; Leukemia, Myeloid, Acute; Mice; Neoplasms; Protein Kinase Inhibitors; Pyrazoles; Structure-Activity Relationship | 2018 |
Discovery of a highly selective FLT3 inhibitor with specific proliferation inhibition against AML cells harboring FLT3-ITD mutation.
Topics: Apoptosis; Cell Cycle Checkpoints; Cell Line; Cell Line, Tumor; Cell Proliferation; Drug Discovery; fms-Like Tyrosine Kinase 3; Humans; Leukemia, Myeloid, Acute; Mutation; Protein Kinase Inhibitors | 2019 |
Combining structure- and property-based optimization to identify selective FLT3-ITD inhibitors with good antitumor efficacy in AML cell inoculated mouse xenograft model.
Topics: Animals; Antineoplastic Agents; Apoptosis; Binding Sites; Cell Line, Tumor; Female; fms-Like Tyrosine Kinase 3; Humans; Leukemia, Myeloid, Acute; Male; Mice, Inbred BALB C; Microsomes, Liver; Molecular Docking Simulation; Molecular Structure; Mutation; Protein Kinase Inhibitors; Pyrazoles; Rats, Sprague-Dawley; Structure-Activity Relationship; Xenograft Model Antitumor Assays | 2019 |
Investigation of Selected Flavonoid Derivatives as Potent FLT3 Inhibitors for the Potential Treatment of Acute Myeloid Leukemia.
Topics: Antineoplastic Agents; Apoptosis; Flavonoids; fms-Like Tyrosine Kinase 3; Humans; Leukemia, Myeloid, Acute; Mutation; Protein Kinase Inhibitors; Xenograft Model Antitumor Assays | 2021 |
Discovery of imidazo[1,2-a]pyridine-thiophene derivatives as FLT3 and FLT3 mutants inhibitors for acute myeloid leukemia through structure-based optimization of an NEK2 inhibitor.
Topics: Antineoplastic Agents; Cell Line, Tumor; Cell Proliferation; Dose-Response Relationship, Drug; Drug Discovery; Drug Screening Assays, Antitumor; fms-Like Tyrosine Kinase 3; Humans; Leukemia, Myeloid, Acute; Molecular Structure; Mutation; NIMA-Related Kinases; Protein Kinase Inhibitors; Pyridines; Structure-Activity Relationship; Thiophenes | 2021 |
Acute myeloid leukemia with cup-like blasts and FLT3-ITD and NPM1 mutations mimics features of acute promyelocytic leukemia: a case of durable remission after sorafenib and low-dose cytarabine.
Topics: Antigens, CD34; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; fms-Like Tyrosine Kinase 3; HLA-DR Antigens; Humans; Leukemia, Myeloid, Acute; Leukemia, Promyelocytic, Acute; Male; Middle Aged; Nucleophosmin; Sorafenib | 2022 |
FMS-like tyrosine kinase-3 (FLT3) inhibitors with better binding affinity and ADMET properties than sorafenib and gilteritinib against acute myeloid leukemia: in silico studies.
Topics: Antineoplastic Agents; fms-Like Tyrosine Kinase 3; Humans; Leukemia, Myeloid, Acute; Molecular Docking Simulation; Mutation; Phenylurea Compounds; Protein Kinase Inhibitors; Sorafenib; Vascular Endothelial Growth Factor Receptor-1 | 2022 |
FLT3-ITD allelic ratio and HLF expression predict FLT3 inhibitor efficacy in adult AML.
Topics: Adult; Aged; Alleles; Antineoplastic Agents; Basic-Leucine Zipper Transcription Factors; Case-Control Studies; Female; fms-Like Tyrosine Kinase 3; Gene Duplication; Gene Expression; Humans; In Vitro Techniques; Leukemia, Myeloid, Acute; Male; Middle Aged; Mutation; Protein Kinase Inhibitors; Retrospective Studies; Sorafenib; Tandem Repeat Sequences; Treatment Outcome | 2021 |
Preclinical and Pilot Study of Type I FLT3 Tyrosine Kinase Inhibitor, Crenolanib, with Sorafenib in Acute Myeloid Leukemia and FLT3-Internal Tandem Duplication.
Topics: Antineoplastic Agents; Benzimidazoles; Child; fms-Like Tyrosine Kinase 3; Humans; Leukemia, Myeloid, Acute; Mutation; Phenylurea Compounds; Pilot Projects; Piperidines; Protein Kinase Inhibitors; Sorafenib | 2022 |
Exploring the Resistance Mechanisms of Distal D835V Mutation in FLT3 to Inhibitors.
Topics: Antineoplastic Agents; Drug Resistance, Neoplasm; fms-Like Tyrosine Kinase 3; Humans; Leukemia, Myeloid, Acute; Mutation; Protein Kinase Inhibitors; Sorafenib | 2022 |
Erythema nodosum after azacitidine in a patient with acute myeloid leukemia.
Topics: Adult; Azacitidine; Erythema Nodosum; Humans; Leukemia, Myeloid, Acute; Male; Recurrence; Sorafenib | 2023 |
Clinical outcomes in patients with relapsed/refractory FLT3-mutated acute myeloid leukemia treated with gilteritinib who received prior midostaurin or sorafenib.
Topics: Aniline Compounds; fms-Like Tyrosine Kinase 3; Humans; Leukemia, Myeloid, Acute; Mutation; Protein Kinase Inhibitors; Pyrazines; Retrospective Studies; Sorafenib; Staurosporine | 2022 |
Autophagy activation mediates resistance to FLT3 inhibitors in acute myeloid leukemia with FLT3-ITD mutation.
Topics: Autophagy; Drug Resistance, Neoplasm; fms-Like Tyrosine Kinase 3; Humans; Leukemia, Myeloid, Acute; Mutation; Protein Kinase Inhibitors; Sorafenib; Tumor Microenvironment | 2022 |
Sorafenib maintenance after hematopoietic stem cell transplantation improves outcome of FLT3-ITD-mutated acute myeloid leukemia.
Topics: fms-Like Tyrosine Kinase 3; Hematopoietic Stem Cell Transplantation; Humans; Leukemia, Myeloid, Acute; Mutation; Niacinamide; Phenylurea Compounds; Recurrence; Retrospective Studies; Sorafenib; Transplantation, Homologous | 2022 |
Bone marrow-targetable Green Tea Catechin-Based Micellar Nanocomplex for synergistic therapy of Acute myeloid leukemia.
Topics: Animals; Bone Marrow; Catechin; Disease Models, Animal; Humans; Leukemia, Myeloid, Acute; Mice; Micelles; Sorafenib; Tea; Tissue Distribution | 2022 |
Disfiguring sorafenib associated eruptive squamous cell carcinomas in a patient with acute myeloid leukemia.
Topics: Carcinoma, Squamous Cell; Exanthema; Humans; Keratoacanthoma; Leukemia, Myeloid, Acute; Skin Neoplasms; Sorafenib | 2023 |
[The clinical safety and efficacy of the patients of acute myeloid leukemia with FLT3-ITD positive treated with sorafenib in combination with venetoclax and azactitidine regimen].
Topics: Antineoplastic Agents; Bridged Bicyclo Compounds, Heterocyclic; fms-Like Tyrosine Kinase 3; Humans; Leukemia, Myeloid, Acute; Mutation; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Sorafenib; Sulfonamides | 2022 |
A Receptor Tyrosine Kinase Inhibitor Sensitivity Prediction Model Identifies AXL Dependency in Leukemia.
Topics: Cell Line, Tumor; Drug Resistance, Neoplasm; fms-Like Tyrosine Kinase 3; Humans; Leukemia, Myeloid, Acute; Mutation; Sorafenib; Tyrosine Kinase Inhibitors | 2023 |
Sorafenib regulates
Topics: Apoptosis; Drug Resistance, Neoplasm; fms-Like Tyrosine Kinase 3; Humans; Leukemia, Myeloid, Acute; Mutation; Proto-Oncogene Proteins c-cbl; Receptor Protein-Tyrosine Kinases; Sorafenib | 2023 |
ART714 is a best-in-class antileukemic 2-carbon-linked dimeric artemisinin derivative.
Topics: Antimalarials; Antineoplastic Agents; Artemisinins; Carbon; Humans; Leukemia, Myeloid, Acute; Sorafenib | 2023 |
Children's Oncology Group's 2023 blueprint for research: Myeloid neoplasms.
Topics: Antineoplastic Agents; Child; fms-Like Tyrosine Kinase 3; Gemtuzumab; Hematopoietic Stem Cell Transplantation; Humans; Leukemia, Myeloid, Acute; Mutation; Prognosis; Sorafenib | 2023 |
Optimising maintenance therapy after transplantation: sorafenib's role in patients with FLT3-ITD acute myeloid leukaemia.
Topics: fms-Like Tyrosine Kinase 3; Humans; Leukemia, Myeloid, Acute; Mutation; Prognosis; Protein Kinase Inhibitors; Sorafenib | 2023 |
Impact of genetic patterns on sorafenib efficacy in patients with FLT3-ITD acute myeloid leukemia undergoing allogeneic hematopoietic stem cell transplantation: a multi-center, cohort study.
Topics: Cohort Studies; fms-Like Tyrosine Kinase 3; Hematopoietic Stem Cell Transplantation; Humans; Leukemia, Myeloid, Acute; Nuclear Proteins; Sorafenib | 2023 |
FLT(3)-ing about: the search for the best inhibitor.
Topics: fms-Like Tyrosine Kinase 3; Humans; Leukemia, Myeloid, Acute; Sorafenib; Tumor Suppressor Proteins | 2023 |
[Effect of Low-Dose Triptolide and Sorafenib Alone and Their Combination on AML Cell Line MV411 and the Pathway of STAT5].
Topics: Apoptosis; Cell Line, Tumor; Diterpenes; Epoxy Compounds; fms-Like Tyrosine Kinase 3; Humans; Leukemia, Myeloid, Acute; Phenanthrenes; Sorafenib; STAT5 Transcription Factor | 2019 |
A Prospective Study of Peritransplant Sorafenib for Patients with FLT3-ITD Acute Myeloid Leukemia Undergoing Allogeneic Transplantation.
Topics: fms-Like Tyrosine Kinase 3; Hematopoietic Stem Cell Transplantation; Humans; Leukemia, Myeloid, Acute; Middle Aged; Niacinamide; Phenylurea Compounds; Prospective Studies; Retrospective Studies; Sorafenib; Transplantation, Homologous | 2020 |
Effects of the multi-kinase inhibitor midostaurin in combination with chemotherapy in models of acute myeloid leukaemia.
Topics: Aniline Compounds; Animals; Antineoplastic Agents; Apoptosis; Benzimidazoles; Benzothiazoles; Cell Line, Tumor; Cell Proliferation; Drug Synergism; fms-Like Tyrosine Kinase 3; Gene Expression Regulation, Neoplastic; Humans; Leukemia, Myeloid, Acute; Mice; Mutation; Phenylurea Compounds; Piperidines; Protein Kinase Inhibitors; Pyrazines; Sorafenib; Staurosporine; Syk Kinase | 2020 |
The Application of Next-generation Sequencing Tumor Molecular Profiling in the Diagnosis and Management of a Case of Acute Myelogenous Leukemia With MLL-PTD in a Pediatric Heart Transplant Recipient.
Topics: Antineoplastic Combined Chemotherapy Protocols; Azacitidine; Child; Combined Modality Therapy; Disease Management; Female; Gene Duplication; Heart Transplantation; Hematopoietic Stem Cell Transplantation; High-Throughput Nucleotide Sequencing; Histone-Lysine N-Methyltransferase; Humans; Leukemia, Myeloid, Acute; Molecular Targeted Therapy; Myeloid-Lymphoid Leukemia Protein; Prognosis; Sorafenib; Tandem Repeat Sequences | 2021 |
[Sorafenib - induced thyroiditis in patient with a relapse of acute myelomonocytic leukemia with FLT3-ITD mutation].
Topics: Antineoplastic Agents; fms-Like Tyrosine Kinase 3; Humans; Leukemia, Myeloid, Acute; Leukemia, Myelomonocytic, Acute; Mutation; Recurrence; Sorafenib; Thyroiditis | 2019 |
Maintenance sorafenib is superior to prophylactic donor lymphocyte infusion at improving the prognosis of acute myeloid leukemia with FMS-like tyrosine kinase 3 internal tandem duplication after allogeneic hematopoietic stem cell transplantation.
Topics: fms-Like Tyrosine Kinase 3; Hematopoietic Stem Cell Transplantation; Humans; Leukemia, Myeloid, Acute; Lymphocytes; Mutation; Prognosis; Sorafenib | 2021 |
Maintenance after allogeneic HSCT in acute myeloid leukaemia.
Topics: fms-Like Tyrosine Kinase 3; Hematopoietic Stem Cell Transplantation; Humans; Leukemia, Myeloid, Acute; Sorafenib | 2020 |
Sorafenib prevents AML relapse after allo-HSCT.
Topics: fms-Like Tyrosine Kinase 3; Hematopoietic Stem Cell Transplantation; Humans; Leukemia, Myeloid, Acute; Maintenance; Mutation; Recurrence; Sorafenib | 2020 |
Activating JAK-mutations confer resistance to FLT3 kinase inhibitors in FLT3-ITD positive AML in vitro and in vivo.
Topics: Cell Line, Tumor; Drug Resistance, Neoplasm; fms-Like Tyrosine Kinase 3; Humans; Janus Kinases; Leukemia, Myeloid, Acute; Mutation; Protein Kinase Inhibitors; Sorafenib; Staurosporine; Tandem Repeat Sequences | 2021 |
Genome-wide CRISPR screen identifies regulators of MAPK and MTOR pathways mediating sorafenib resistance in acute myeloid leukemia.
Topics: Antineoplastic Agents; Cell Line, Tumor; Clustered Regularly Interspaced Short Palindromic Repeats; fms-Like Tyrosine Kinase 3; Humans; Leukemia, Myeloid, Acute; MAP Kinase Signaling System; Mutation; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Sorafenib; TOR Serine-Threonine Kinases; Transcription Factors | 2022 |
Pre-emptive use of Sorafenib combined with DLI post HSCT in AML FLT3+: a single center experience.
Topics: fms-Like Tyrosine Kinase 3; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; Humans; Leukemia, Myeloid, Acute; Mutation; Sorafenib | 2021 |
Case of neutrophilic eccrine hidradenitis resembling acanthosis nigricans in a patient with acute myeloid leukemia associated with azacitidine and sorafenib.
Topics: Acanthosis Nigricans; Azacitidine; Hidradenitis; Humans; Leukemia, Myeloid, Acute; Sorafenib | 2021 |
Post-transplantation maintenance with sorafenib or midostaurin for FLT3 positive AML patients - a multicenter retrospective observational study.
Topics: fms-Like Tyrosine Kinase 3; Hematopoietic Stem Cell Transplantation; Humans; Leukemia, Myeloid, Acute; Protein Kinase Inhibitors; Sorafenib; Staurosporine | 2021 |
FLT3 tyrosine kinase inhibitors synergize with BCL-2 inhibition to eliminate FLT3/ITD acute leukemia cells through BIM activation.
Topics: Bcl-2-Like Protein 11; Bridged Bicyclo Compounds, Heterocyclic; fms-Like Tyrosine Kinase 3; HL-60 Cells; Humans; Leukemia, Myeloid, Acute; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-bcl-2; Sorafenib; Sulfonamides; THP-1 Cells | 2021 |
Pharmacophore-inspired discovery of FLT3 inhibitor from kimchi.
Topics: Animals; Cell Line, Tumor; Fermented Foods; fms-Like Tyrosine Kinase 3; Humans; Leukemia, Myeloid, Acute; Mice; Mutation; Phosphorylation; Sorafenib | 2021 |
The combination of PRL-3 inhibitor with sorafenib synergistically promotes AML apoptosis.
Topics: Apoptosis; Cell Line, Tumor; Cell Proliferation; Humans; Leukemia, Myeloid, Acute; Liver; Phosphatidylinositol 3-Kinases; Sorafenib | 2021 |
Safety of FLT3 inhibitors in patients with acute myeloid leukemia.
Topics: Antineoplastic Agents; fms-Like Tyrosine Kinase 3; Humans; Leukemia, Myeloid, Acute; Mutation; Protein Kinase Inhibitors; Sorafenib | 2021 |
Efficacy and feasibility of sorafenib as a maintenance agent after allogeneic hematopoietic stem cell transplantation for Fms-like tyrosine kinase 3-mutated acute myeloid leukemia.
Topics: Adolescent; Adult; Antineoplastic Agents; Chemotherapy, Adjuvant; Disease-Free Survival; Feasibility Studies; Female; fms-Like Tyrosine Kinase 3; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; Humans; Leukemia, Myeloid, Acute; Maintenance Chemotherapy; Male; Middle Aged; Niacinamide; Phenylurea Compounds; Retrospective Studies; Sorafenib; Transplantation, Homologous; Treatment Outcome; Young Adult | 2017 |
Phosphoproteome Analysis Reveals Differential Mode of Action of Sorafenib in Wildtype and Mutated FLT3 Acute Myeloid Leukemia (AML) Cells.
Topics: Cell Line, Tumor; Cell Proliferation; Cell Survival; fms-Like Tyrosine Kinase 3; Gene Regulatory Networks; Humans; Inhibitory Concentration 50; Leukemia, Myeloid, Acute; Mutation; Niacinamide; Phenylurea Compounds; Phosphoproteins; Protein Kinase Inhibitors; Proteomics; Sorafenib | 2017 |
Midostaurin Gets FDA Nod for AML.
Topics: Drug Approval; fms-Like Tyrosine Kinase 3; Humans; Leukemia, Myeloid, Acute; Niacinamide; Phenylurea Compounds; Sorafenib; Staurosporine; Treatment Outcome; United States; United States Food and Drug Administration | 2017 |
Adaptation to TKI Treatment Reactivates ERK Signaling in Tyrosine Kinase-Driven Leukemias and Other Malignancies.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Benzamides; Cell Line, Tumor; Cell Proliferation; Diphenylamine; Female; HL-60 Cells; Humans; K562 Cells; Leukemia, Myeloid, Acute; MAP Kinase Signaling System; Mice; Mice, Inbred NOD; Mice, SCID; Neoplasms; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Random Allocation; Sorafenib; Xenograft Model Antitumor Assays | 2017 |
Long-term survival of sorafenib-treated FLT3-ITD-positive acute myeloid leukaemia patients relapsing after allogeneic stem cell transplantation.
Topics: Adolescent; Adult; Aged; Antineoplastic Agents; Biomarkers, Tumor; Disease Progression; Disease-Free Survival; Female; fms-Like Tyrosine Kinase 3; Germany; Humans; Kaplan-Meier Estimate; Leukemia, Myeloid, Acute; Male; Middle Aged; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Recurrence; Remission Induction; Retrospective Studies; Risk Factors; Sorafenib; Stem Cell Transplantation; Tandem Repeat Sequences; Time Factors; Transplantation, Homologous; Treatment Outcome; Young Adult | 2017 |
Hypoxia-induced upregulation of BMX kinase mediates therapeutic resistance in acute myeloid leukemia.
Topics: Cell Hypoxia; Child; Child, Preschool; Drug Resistance, Neoplasm; Female; fms-Like Tyrosine Kinase 3; Gene Expression Regulation, Enzymologic; Gene Expression Regulation, Leukemic; Humans; Infant; Leukemia, Myeloid, Acute; Male; Protein-Tyrosine Kinases; Signal Transduction; Sorafenib; Tumor Microenvironment; Up-Regulation | 2018 |
The sorafenib anti-relapse effect after alloHSCT is associated with heightened alloreactivity and accumulation of CD8+PD-1+ (CD279+) lymphocytes in marrow.
Topics: Antineoplastic Agents; Bone Marrow Cells; CD8 Antigens; Female; Hematopoietic Stem Cell Transplantation; Humans; Leukemia, Myeloid, Acute; Lymphocytes; Male; Middle Aged; Niacinamide; Phenylurea Compounds; Programmed Cell Death 1 Receptor; Recurrence; Sorafenib; Transplantation, Homologous | 2018 |
Sorafenib promotes graft-versus-leukemia activity in mice and humans through IL-15 production in FLT3-ITD-mutant leukemia cells.
Topics: Activating Transcription Factor 4; Animals; CD8-Positive T-Lymphocytes; Cellular Reprogramming; fms-Like Tyrosine Kinase 3; Gene Expression Regulation, Neoplastic; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; Humans; Interferon Regulatory Factor-7; Interleukin-15; Leukemia, Myeloid, Acute; Mice; Sorafenib; Tandem Repeat Sequences; Transplantation, Homologous | 2018 |
Effect of sorafenib on the outcomes of patients with FLT3-ITD acute myeloid leukemia undergoing allogeneic hematopoietic stem cell transplantation.
Topics: Adult; Combined Modality Therapy; Disease-Free Survival; Female; fms-Like Tyrosine Kinase 3; Follow-Up Studies; Gain of Function Mutation; Hematopoietic Stem Cell Transplantation; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged; Mutation; Neoplasm Recurrence, Local; Protein Domains; Protein Kinase Inhibitors; Remission Induction; Retrospective Studies; Segmental Duplications, Genomic; Sorafenib; Survival Rate; Tandem Repeat Sequences; Transplantation, Homologous; Young Adult | 2018 |
Sorafenib as a Salvage Therapy in FLT3-ITD Negative Relapse/ Refractory Acute Myeloid Leukemia.
Topics: Adolescent; Antineoplastic Agents; Dose-Response Relationship, Drug; Drug Screening Assays, Antitumor; fms-Like Tyrosine Kinase 3; Humans; Leukemia, Myeloid, Acute; Magnetic Resonance Imaging; Male; Middle Aged; Molecular Structure; Neoplasm, Residual; Protein Kinase Inhibitors; Salvage Therapy; Sorafenib; Structure-Activity Relationship | 2018 |
[Sorafenib combined with chemotherapy and donor lymphocyte infusion as salvage therapy in patients with FLT3-positive acute myeloid leukemia relapse after allogeneic hematopoietic stem cell transplantation].
Topics: Antineoplastic Agents; Combined Modality Therapy; Disease-Free Survival; fms-Like Tyrosine Kinase 3; Hematopoietic Stem Cell Transplantation; Humans; Immunotherapy, Adoptive; Leukemia, Myeloid, Acute; Niacinamide; Phenylurea Compounds; Recurrence; Remission Induction; Salvage Therapy; Sorafenib; Transplantation, Homologous; Treatment Outcome | 2018 |
Epigenetic modification enhances the cytotoxicity of busulfan and4-hydroperoxycyclophosphamide in AML cells.
Topics: Alkylating Agents; Apoptosis; Busulfan; Cell Line, Tumor; Chromatin; Cyclophosphamide; Decitabine; DNA (Cytosine-5-)-Methyltransferase 1; DNA Damage; DNA Methylation; Drug Screening Assays, Antitumor; Drug Synergism; fms-Like Tyrosine Kinase 3; Gene Duplication; Genes, p53; Humans; Leukemia, Myeloid, Acute; Membrane Potential, Mitochondrial; Neoplasm Proteins; Oxidative Stress; Precision Medicine; Signal Transduction; Sorafenib; Transplantation Conditioning | 2018 |
Late relapse after stopping sorafenib in allogeneic hematopoietic stem cell transplant recipients.
Topics: Adult; Female; Hematopoietic Stem Cell Transplantation; Humans; Leukemia, Myeloid, Acute; Male; Recurrence; Sorafenib | 2019 |
Discontinuation of sorafenib can lead to the emergence of FLT3-ITD-positive acute myeloid leukemia.
Topics: Aged; Female; fms-Like Tyrosine Kinase 3; Humans; Leukemia, Myeloid, Acute; Mutation; Protein Kinase Inhibitors; Sorafenib | 2019 |
Dose-related periorbital edema following sorafenib in a patient with acute myeloid leukemia.
Topics: Aged; Antineoplastic Agents; Edema; fms-Like Tyrosine Kinase 3; Humans; Leukemia, Myeloid, Acute; Male; Mutation; Sorafenib; Voriconazole | 2019 |
Fulminant Vascular and Cardiac Toxicity Associated with Tyrosine Kinase Inhibitor Sorafenib.
Topics: Adult; Antineoplastic Agents; Cardiotoxicity; Cardiovascular Agents; Coronary Artery Disease; Coronary Restenosis; Defibrillators; Defibrillators, Implantable; Drug-Eluting Stents; Electric Countershock; Endovascular Procedures; Humans; Intra-Aortic Balloon Pumping; Leukemia, Myeloid, Acute; Male; Myocardial Infarction; Peripheral Arterial Disease; Protein Kinase Inhibitors; Sorafenib; Treatment Outcome | 2019 |
Combination of sorafenib, vorinostat and bortezomib for the treatment of poor-risk AML: report of two consecutive clinical trials.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bortezomib; Clinical Trials, Phase I as Topic; Clinical Trials, Phase II as Topic; Cohort Studies; Female; Follow-Up Studies; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged; Prognosis; Sorafenib; Vorinostat | 2019 |
Sorafenib improves survival of
Topics: Adult; Aged; Antineoplastic Agents; Female; fms-Like Tyrosine Kinase 3; Gene Duplication; Hematopoietic Stem Cell Transplantation; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged; Mutation; Neoplasm Recurrence, Local; Registries; Remission Induction; Retrospective Studies; Salvage Therapy; Sorafenib; Transplantation, Homologous; Treatment Outcome; Young Adult | 2019 |
Maintenance sorafenib in FLT3-ITD AML following allogeneic HCT favorably impacts relapse and overall survival.
Topics: Allografts; Disease-Free Survival; fms-Like Tyrosine Kinase 3; Humans; Leukemia, Myeloid, Acute; Maintenance Chemotherapy; Male; Middle Aged; Recurrence; Retrospective Studies; Sorafenib; Survival Rate | 2019 |
Efficacy and Feasibility of Sorafenib as a Maintenance Agent After Allogeneic Hematopoietic Stem Cell Transplantation for Fms-like Tyrosine Kinase 3 Mutated Acute Myeloid Leukemia: An Update.
Topics: Adolescent; Adult; Cohort Studies; Combined Modality Therapy; Feasibility Studies; Female; fms-Like Tyrosine Kinase 3; Follow-Up Studies; Hematopoietic Stem Cell Transplantation; Humans; Leukemia, Myeloid, Acute; Maintenance Chemotherapy; Male; Middle Aged; Mutation; Prognosis; Protein Kinase Inhibitors; Remission Induction; Sorafenib; Survival Rate; Transplantation, Homologous; Young Adult | 2019 |
Activity of ponatinib against clinically-relevant AC220-resistant kinase domain mutants of FLT3-ITD.
Topics: Amino Acid Sequence; Amino Acid Substitution; Benzothiazoles; Cell Line, Tumor; Drug Resistance, Neoplasm; fms-Like Tyrosine Kinase 3; Gene Duplication; Humans; Imidazoles; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Leukemia, Myeloid, Acute; Molecular Docking Simulation; Molecular Sequence Data; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Protein Structure, Tertiary; Pyridazines; Quinolines; Sorafenib | 2013 |
Simultaneous inhibition of aberrant cancer kinome using rationally designed polymer-protein core-shell nanomedicine.
Topics: Antineoplastic Agents; Cell Line, Tumor; Drug Delivery Systems; Everolimus; Humans; Leukemia, Myeloid, Acute; Mitogen-Activated Protein Kinases; Models, Molecular; Nanomedicine; Niacinamide; Phenylurea Compounds; Polyglactin 910; Protein Kinase Inhibitors; Sialic Acid Binding Ig-like Lectin 3; Sirolimus; Sorafenib; STAT5 Transcription Factor; TOR Serine-Threonine Kinases | 2013 |
Emergence of polyclonal FLT3 tyrosine kinase domain mutations during sequential therapy with sorafenib and sunitinib in FLT3-ITD-positive acute myeloid leukemia.
Topics: Adolescent; Alleles; Animals; Antineoplastic Agents; Cell Line, Tumor; Child; Drug Resistance, Neoplasm; Female; fms-Like Tyrosine Kinase 3; Humans; Indoles; Leukemia, Myeloid, Acute; Male; Mice; Models, Molecular; Molecular Conformation; Mutation; Niacinamide; Phenylurea Compounds; Protein Binding; Protein Interaction Domains and Motifs; Protein Kinase Inhibitors; Pyrroles; Sorafenib; Sunitinib; Treatment Outcome | 2013 |
[Sorafenib monotherapy for FLT3-ITD positive acute myeloid leukemia: a case report].
Topics: fms-Like Tyrosine Kinase 3; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged; Mutation; Niacinamide; Phenylurea Compounds; Sorafenib | 2013 |
Crenolanib is active against models of drug-resistant FLT3-ITD-positive acute myeloid leukemia.
Topics: Animals; Antineoplastic Agents; Benzimidazoles; Cell Line, Tumor; Cell Survival; Drug Resistance, Neoplasm; Drug Synergism; Female; fms-Like Tyrosine Kinase 3; Humans; Leukemia, Myeloid, Acute; Male; Mice; Mice, Inbred NOD; Mice, SCID; Mutation; Niacinamide; Phenylurea Compounds; Piperidines; Protein Kinase Inhibitors; Sorafenib; Tandem Repeat Sequences; Xenograft Model Antitumor Assays | 2013 |
Sorafenib as monotherapy or in association with cytarabine and clofarabine for the treatment of relapsed/refractory FLT3 ITD-positive advanced acute myeloid leukemia.
Topics: Adenine Nucleotides; Adult; Arabinonucleosides; Clofarabine; Cytarabine; Female; fms-Like Tyrosine Kinase 3; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged; Mutation; Neoplasm Recurrence, Local; Niacinamide; Phenylurea Compounds; Sorafenib; Tandem Repeat Sequences; Young Adult | 2014 |
Preclinical evaluation of AMG 925, a FLT3/CDK4 dual kinase inhibitor for treating acute myeloid leukemia.
Topics: Animals; Apoptosis; Cell Cycle; Cell Line, Tumor; Cell Proliferation; Cyclin-Dependent Kinase 4; Dose-Response Relationship, Drug; fms-Like Tyrosine Kinase 3; Heterocyclic Compounds, 3-Ring; Humans; Leukemia, Myeloid, Acute; Mice; Mice, Nude; Naphthyridines; Neoplasms, Experimental; Niacinamide; Phenylurea Compounds; Piperazines; Protein Kinase Inhibitors; Pyridines; Signal Transduction; Sorafenib; U937 Cells; Xenograft Model Antitumor Assays | 2014 |
A novel tescalcin-sodium/hydrogen exchange axis underlying sorafenib resistance in FLT3-ITD+ AML.
Topics: Animals; Antineoplastic Agents; Calcium-Binding Proteins; Cation Transport Proteins; Cells, Cultured; Drug Resistance, Neoplasm; fms-Like Tyrosine Kinase 3; Humans; Hydrogen-Ion Concentration; Intracellular Space; K562 Cells; Leukemia, Myeloid, Acute; Mice; Mice, Inbred NOD; Mice, SCID; Niacinamide; Phenylurea Compounds; Signal Transduction; Sodium-Hydrogen Exchanger 1; Sodium-Hydrogen Exchangers; Sorafenib; Tandem Repeat Sequences | 2014 |
Reversal of acquired drug resistance in FLT3-mutated acute myeloid leukemia cells via distinct drug combination strategies.
Topics: Animals; Antineoplastic Agents; Apoptosis; Cell Line, Tumor; Cell Survival; DNA Mutational Analysis; Dose-Response Relationship, Drug; Drug Resistance, Neoplasm; Drug Synergism; fms-Like Tyrosine Kinase 3; Gene Duplication; Humans; Leukemia, Myeloid, Acute; Membrane Proteins; Mice; Mutation; Niacinamide; Phenylurea Compounds; Point Mutation; Protein Interaction Domains and Motifs; Protein Kinase Inhibitors; Signal Transduction; Sorafenib; Tandem Repeat Sequences | 2014 |
Sorafenib plus all-trans retinoic acid for AML patients with FLT3-ITD and NPM1 mutations.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Fatal Outcome; Female; fms-Like Tyrosine Kinase 3; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged; Mutation; Niacinamide; Nuclear Proteins; Nucleophosmin; Phenylurea Compounds; Sorafenib; Treatment Outcome; Tretinoin; Young Adult | 2014 |
Treatment with FLT3 inhibitor in patients with FLT3-mutated acute myeloid leukemia is associated with development of secondary FLT3-tyrosine kinase domain mutations.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Benzothiazoles; Carbazoles; DNA Mutational Analysis; Female; fms-Like Tyrosine Kinase 3; Furans; Humans; Leukemia, Myeloid, Acute; Male; Medical Records; Middle Aged; Mutation; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Retrospective Studies; Sorafenib; Survival Analysis; Treatment Outcome | 2014 |
Sorafenib is tolerable and improves clinical outcomes in patients with FLT3-ITD acute myeloid leukemia prior to stem cell transplant and after relapse post-transplant.
Topics: Adult; Aged; Antineoplastic Agents; Female; fms-Like Tyrosine Kinase 3; Hematopoietic Stem Cell Transplantation; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged; Niacinamide; Phenylurea Compounds; Remission Induction; Retreatment; Retrospective Studies; Sorafenib; Tandem Repeat Sequences; Treatment Outcome | 2014 |
Use of sorafenib for post-transplant relapse in FLT3/ITD-positive acute myelogenous leukemia: maturation induction and cytotoxic effect.
Topics: Antineoplastic Agents; Bone Marrow; Female; fms-Like Tyrosine Kinase 3; Gene Duplication; Hematopoietic Stem Cell Transplantation; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged; Mutation; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Recurrence; Retreatment; Sorafenib; Tandem Repeat Sequences; Transplantation, Homologous; Treatment Outcome | 2014 |
Extensive Squamous Cell Carcinoma of the Skin Related to Use of Sorafenib for Treatment of FLT3-Mutant Acute Myeloid Leukemia.
Topics: Aged; Antineoplastic Agents; Carcinoma, Squamous Cell; fms-Like Tyrosine Kinase 3; Humans; Leukemia, Myeloid, Acute; Male; Mutation; Niacinamide; Phenylurea Compounds; Skin Neoplasms; Sorafenib | 2016 |
Sorafenib priming may augment salvage chemotherapy in relapsed and refractory FLT3-ITD-positive acute myeloid leukemia.
Topics: Adolescent; Adult; Antineoplastic Agents; Female; fms-Like Tyrosine Kinase 3; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged; Mutation; Niacinamide; Phenylurea Compounds; Salvage Therapy; Sorafenib | 2014 |
Synergistic cytotoxicity of sorafenib with busulfan and nucleoside analogs in human FMS-like tyrosine kinase 3 internal tandem duplications-positive acute myeloid leukemia cells.
Topics: Adenine Nucleotides; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Arabinonucleosides; Busulfan; Clofarabine; DNA Damage; Drug Synergism; fms-Like Tyrosine Kinase 3; Humans; Leukemia, Myeloid, Acute; Niacinamide; Phenylurea Compounds; Phosphorylation; Sorafenib; Tandem Repeat Sequences; Vidarabine | 2014 |
FLT3 and CDK4/6 inhibitors: signaling mechanisms and tumor burden in subcutaneous and orthotopic mouse models of acute myeloid leukemia.
Topics: Animals; Benzothiazoles; Cell Line, Tumor; Cyclin-Dependent Kinase 4; Cyclin-Dependent Kinase 6; Disease Models, Animal; fms-Like Tyrosine Kinase 3; Leukemia, Myeloid, Acute; Mice; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Signal Transduction; Sorafenib; Tumor Burden | 2014 |
Inhibition of c-Kit by tyrosine kinase inhibitors.
Topics: Aminopyridines; Antineoplastic Agents; Benzothiazoles; Biomarkers; Bone Marrow; Cell Line, Tumor; Clinical Trials as Topic; Dasatinib; fms-Like Tyrosine Kinase 3; Gene Expression; Hair; Hematopoietic Stem Cells; Humans; Indazoles; Leukemia, Myeloid, Acute; Niacinamide; Phenylurea Compounds; Pigmentation; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-kit; Pyrimidines; Pyrroles; Sorafenib; Sulfonamides; Thiazoles | 2015 |
Sorafenib Maintenance Appears Safe and Improves Clinical Outcomes in FLT3-ITD Acute Myeloid Leukemia After Allogeneic Hematopoietic Cell Transplantation.
Topics: Adult; Antineoplastic Agents; Combined Modality Therapy; fms-Like Tyrosine Kinase 3; Gene Duplication; Hematopoietic Stem Cell Transplantation; Humans; Leukemia, Myeloid, Acute; Maintenance Chemotherapy; Male; Middle Aged; Niacinamide; Off-Label Use; Phenylurea Compounds; Retrospective Studies; Sorafenib; Transplantation, Homologous; Treatment Outcome | 2015 |
Sorafenib treatment following hematopoietic stem cell transplant in pediatric FLT3/ITD acute myeloid leukemia.
Topics: Adolescent; Adult; Antineoplastic Agents; Child; fms-Like Tyrosine Kinase 3; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; Humans; Leukemia, Myeloid, Acute; Neoplasm, Residual; Niacinamide; Phenylurea Compounds; Retrospective Studies; Sorafenib; Tandem Repeat Sequences | 2015 |
Sorafenib induces paradoxical phosphorylation of the extracellular signal-regulated kinase pathway in acute myeloid leukemia cells lacking FLT3-ITD mutation.
Topics: Animals; Antineoplastic Agents; Apoptosis; Cell Line, Tumor; Cell Proliferation; Extracellular Signal-Regulated MAP Kinases; fms-Like Tyrosine Kinase 3; Gene Expression; Humans; Leukemia, Myeloid, Acute; Mice; Mutation; Niacinamide; Phenylurea Compounds; Phosphorylation; Protein Kinase Inhibitors; raf Kinases; Signal Transduction; Sorafenib; Tandem Repeat Sequences | 2015 |
Azacitidine as post-remission consolidation for sorafenib-induced remission of Fms-like tyrosine kinase-3 internal tandem duplication positive acute myeloid leukemia.
Topics: Animals; Antineoplastic Agents; Apoptosis; Azacitidine; Cell Line, Tumor; Drug Administration Schedule; Drug Synergism; fms-Like Tyrosine Kinase 3; Gene Expression; Humans; Leukemia, Myeloid, Acute; Mice; Monocytes; Mutation; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Remission Induction; Sorafenib; Survival Analysis; Treatment Outcome; Xenograft Model Antitumor Assays | 2015 |
[CLAG regimen in combination with sorafenib in the treatment of refractory acute myeloid leukemia:a case report].
Topics: Antineoplastic Combined Chemotherapy Protocols; Humans; Leukemia, Myeloid, Acute; Niacinamide; Phenylurea Compounds; Sorafenib | 2015 |
Sorafenib in Relapsed AML With FMS-Like Receptor Tyrosine Kinase-3 Internal Tandem Duplication Mutation.
Topics: Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; fms-Like Tyrosine Kinase 3; Gene Duplication; Humans; Leukemia, Myeloid, Acute; Male; Mutation; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Recurrence; Sorafenib; Tandem Repeat Sequences; Treatment Outcome | 2015 |
NFATc1 as a therapeutic target in FLT3-ITD-positive AML.
Topics: Apoptosis; Biomarkers, Tumor; Blotting, Western; Cell Proliferation; Cyclosporine; Drug Resistance, Neoplasm; Flow Cytometry; fms-Like Tyrosine Kinase 3; Gene Expression Profiling; Humans; Immunoenzyme Techniques; Immunosuppressive Agents; Leukemia, Myeloid, Acute; Mutation; Neoplasm Recurrence, Local; Neoplasm Staging; NFATC Transcription Factors; Niacinamide; Oligonucleotide Array Sequence Analysis; Phenylurea Compounds; Prognosis; Protein Kinase Inhibitors; Real-Time Polymerase Chain Reaction; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; RNA, Small Interfering; Sorafenib; Survival Rate; Tandem Repeat Sequences; Tumor Cells, Cultured | 2015 |
Integration of Hedgehog and mutant FLT3 signaling in myeloid leukemia.
Topics: Animals; Cell Compartmentation; Cell Line, Tumor; Cell Proliferation; Cell Survival; Disease Progression; Drug Synergism; fms-Like Tyrosine Kinase 3; Gene Duplication; Hedgehog Proteins; Humans; Kruppel-Like Transcription Factors; Leukemia, Myeloid, Acute; Mice; Mutant Proteins; Myeloproliferative Disorders; Niacinamide; Nuclear Proteins; Phenylurea Compounds; Receptors, G-Protein-Coupled; Signal Transduction; Smoothened Receptor; Sorafenib; STAT5 Transcription Factor; Stem Cells; Veratrum Alkaloids; Zinc Finger Protein Gli2 | 2015 |
Synergistic effect of sorafenib and cGvHD in patients with high-risk FLT3-ITD+AML allows long-term disease control after allogeneic transplantation.
Topics: Adult; Aged; Female; fms-Like Tyrosine Kinase 3; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; Humans; Induction Chemotherapy; Leukemia, Myeloid, Acute; Male; Middle Aged; Mutation; Niacinamide; Phenylurea Compounds; Remission Induction; Retrospective Studies; Risk Factors; Sorafenib; Tandem Repeat Sequences; Transplantation Conditioning; Transplantation, Homologous; Treatment Outcome; Young Adult | 2015 |
High rate of hematological responses to sorafenib in FLT3-ITD acute myeloid leukemia relapsed after allogeneic hematopoietic stem cell transplantation.
Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; Female; fms-Like Tyrosine Kinase 3; Hematopoietic Stem Cell Transplantation; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Retreatment; Retrospective Studies; Sorafenib; Tandem Repeat Sequences; Transplantation, Homologous; Treatment Outcome | 2016 |
Decitabine and Sorafenib Therapy in FLT-3 ITD-Mutant Acute Myeloid Leukemia.
Topics: Azacitidine; Cell Line, Tumor; Decitabine; Female; fms-Like Tyrosine Kinase 3; Humans; Leukemia, Myeloid, Acute; Middle Aged; Mutation; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Sorafenib; Survival Analysis | 2015 |
Improvement in clinical outcome of FLT3 ITD mutated acute myeloid leukemia patients over the last one and a half decade.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Analysis of Variance; Antineoplastic Agents; Female; fms-Like Tyrosine Kinase 3; Gene Expression; Hematopoietic Stem Cell Transplantation; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged; Mutation; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Recurrence; Remission Induction; Retrospective Studies; Sorafenib; Survival Analysis; Transplantation, Homologous; Treatment Outcome | 2015 |
Sorafenib Inhibition of Mcl-1 Accelerates ATRA-Induced Apoptosis in Differentiation-Responsive AML Cells.
Topics: Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Cell Differentiation; Gene Expression Regulation, Neoplastic; Glycogen Synthase Kinase 3 beta; HL-60 Cells; Humans; Leukemia, Myeloid, Acute; Leukemia, Promyelocytic, Acute; Myeloid Cell Leukemia Sequence 1 Protein; Niacinamide; Phenylurea Compounds; Phosphatidylinositol 3-Kinases; Proto-Oncogene Proteins c-bcl-2; RNA, Small Interfering; Sorafenib; Tretinoin; Xenograft Model Antitumor Assays | 2016 |
Azacitidine and Sorafenib Therapy in a Pediatric Patient With Refractory Acute Myeloid Leukemia With Monosomy 7 and Somatic PTPN11 Mutation.
Topics: Antimetabolites, Antineoplastic; Antineoplastic Agents; Azacitidine; Child, Preschool; Chromosome Deletion; Chromosomes, Human, Pair 7; Drug Therapy, Combination; Female; Humans; Leukemia, Myeloid, Acute; Mutation; Niacinamide; Phenylurea Compounds; Protein Tyrosine Phosphatase, Non-Receptor Type 11; Sorafenib; Stem Cell Transplantation | 2016 |
Metformin synergistically sensitizes FLT3-ITD-positive acute myeloid leukemia to sorafenib by promoting mTOR-mediated apoptosis and autophagy.
Topics: Adaptor Proteins, Signal Transducing; AMP-Activated Protein Kinases; Antineoplastic Agents; Apoptosis; Autophagy; Biomarkers; Cell Cycle; Cell Cycle Proteins; Cell Line, Tumor; Drug Synergism; Enzyme Activation; fms-Like Tyrosine Kinase 3; Humans; Leukemia, Myeloid, Acute; Metformin; Microtubule-Associated Proteins; Molecular Targeted Therapy; Mutation; Neoplasm Proteins; Neoplastic Stem Cells; Niacinamide; Phenylurea Compounds; Phosphoproteins; Phosphorylation; Protein Kinase Inhibitors; Protein Processing, Post-Translational; Ribosomal Protein S6 Kinases, 70-kDa; Signal Transduction; Sorafenib; Tandem Repeat Sequences; TOR Serine-Threonine Kinases | 2015 |
Sorafenib and novel multikinase inhibitors in AML.
Topics: Antineoplastic Combined Chemotherapy Protocols; Female; Humans; Leukemia, Myeloid, Acute; Male; Neoadjuvant Therapy; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Sorafenib | 2015 |
Sorafenib-induced Posterior Reversible Encephalopathy Syndrome in a Child With FLT3-ITD-positive Acute Myeloid Leukemia.
Topics: Antineoplastic Agents; Child; fms-Like Tyrosine Kinase 3; Humans; Leukemia, Myeloid, Acute; Male; Neoplasm Recurrence, Local; Niacinamide; Phenylurea Compounds; Posterior Leukoencephalopathy Syndrome; Salvage Therapy; Sorafenib | 2016 |
Continuous molecular remission and regression of side effects after discontinuation of salvage therapy with sorafenib and donor lymphocyte infusions in a young patient with relapsed AML.
Topics: Alopecia; Antineoplastic Agents; Child, Preschool; Female; Humans; Leukemia, Myeloid, Acute; Lymphocyte Transfusion; Neoplasm Recurrence, Local; Niacinamide; Phenylurea Compounds; Salvage Therapy; Sorafenib; Tissue Donors | 2016 |
Aberrant activation of the PI3K/mTOR pathway promotes resistance to sorafenib in AML.
Topics: Animals; Antineoplastic Agents; Apoptosis; Cell Line, Tumor; Cell Proliferation; Drug Resistance, Neoplasm; fms-Like Tyrosine Kinase 3; Humans; Leukemia, Myeloid, Acute; Mice; Morpholines; Mutation; Niacinamide; Phenylurea Compounds; Phosphatidylinositol 3-Kinases; Phosphoinositide-3 Kinase Inhibitors; Protein Kinase Inhibitors; Signal Transduction; Sorafenib; TOR Serine-Threonine Kinases; Triazines; Xenograft Model Antitumor Assays | 2016 |
[Improved clinical outcome of acute myeloid leukemia with FLT3-ITD mutation treated with sorafenib].
Topics: Antineoplastic Agents; Disease-Free Survival; fms-Like Tyrosine Kinase 3; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; Humans; Leukemia, Myeloid, Acute; Mutation; Niacinamide; Phenylurea Compounds; Remission Induction; Retrospective Studies; Sorafenib; Survival Rate; Treatment Outcome | 2016 |
[Sorafenib as salvage therapy in refractory relapsed acute myeloid leukemia with positive FLT3 mutation].
Topics: Antineoplastic Agents; Disease-Free Survival; fms-Like Tyrosine Kinase 3; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; Humans; Induction Chemotherapy; Leukemia, Myeloid, Acute; Mutation; Niacinamide; Phenylurea Compounds; Recurrence; Remission Induction; Retrospective Studies; Salvage Therapy; Sorafenib; Treatment Outcome | 2016 |
All-trans retinoic acid synergizes with FLT3 inhibition to eliminate FLT3/ITD+ leukemia stem cells in vitro and in vivo.
Topics: Animals; Cell Death; Cell Line, Tumor; Drug Resistance, Neoplasm; Drug Synergism; fms-Like Tyrosine Kinase 3; Gene Duplication; Humans; Leukemia, Myeloid, Acute; Mice; Mutant Proteins; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Sorafenib; Tandem Repeat Sequences; Tretinoin; Xenograft Model Antitumor Assays | 2016 |
Metabolic alterations and drug sensitivity of tyrosine kinase inhibitor resistant leukemia cells with a FLT3/ITD mutation.
Topics: Angiogenesis Inhibitors; Animals; Apoptosis; Cell Line, Tumor; Cell Proliferation; Deoxyglucose; Dose-Response Relationship, Drug; Drug Resistance, Neoplasm; fms-Like Tyrosine Kinase 3; G2 Phase Cell Cycle Checkpoints; Genetic Predisposition to Disease; Glycolysis; Humans; Leukemia, Myeloid, Acute; Mice; Mitochondria; Mutation; Niacinamide; Phenotype; Phenylurea Compounds; Protein Kinase Inhibitors; Pyruvates; Signal Transduction; Sorafenib; Tandem Repeat Sequences; Time Factors | 2016 |
[Clinical Efficacy of Sorafenib Combined with Low Dose Cytarabine for Treating Patients with FLT3+ Relapsed and Refractory Acute Myeloid Leukemia].
Topics: Cytarabine; fms-Like Tyrosine Kinase 3; Humans; Leukemia, Myeloid, Acute; Niacinamide; Phenylurea Compounds; Recurrence; Remission Induction; Sorafenib; Treatment Outcome | 2016 |
Identification of a germline F692L drug resistance variant in cis with Flt3-internal tandem duplication in knock-in mice.
Topics: Animals; Benzothiazoles; Drug Resistance; fms-Like Tyrosine Kinase 3; Gene Knock-In Techniques; Germ-Line Mutation; Humans; Leukemia, Myeloid, Acute; Mice; Niacinamide; Phenylurea Compounds; Sorafenib; Tandem Repeat Sequences; Tumor Cells, Cultured | 2016 |
Integrin alphavbeta3 enhances β-catenin signaling in acute myeloid leukemia harboring Fms-like tyrosine kinase-3 internal tandem duplication mutations: implications for microenvironment influence on sorafenib sensitivity.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Apoptosis; beta Catenin; Cell Line, Tumor; Cell Survival; Female; fms-Like Tyrosine Kinase 3; Gene Expression Regulation, Leukemic; Humans; Integrin alphaVbeta3; Kaplan-Meier Estimate; Leukemia, Myeloid, Acute; Male; Middle Aged; Mutation; Niacinamide; Osteopontin; Phenylurea Compounds; Prognosis; Risk; Signal Transduction; Sorafenib; Tumor Microenvironment | 2016 |
Activation of protein phosphatase 2A in FLT3+ acute myeloid leukemia cells enhances the cytotoxicity of FLT3 tyrosine kinase inhibitors.
Topics: Animals; Cell Line, Tumor; Enzyme Activation; Fingolimod Hydrochloride; fms-Like Tyrosine Kinase 3; Humans; Leukemia, Myeloid, Acute; Mice; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Protein Phosphatase 2; Sorafenib | 2016 |
Haematopoietic cell transplantation with and without sorafenib maintenance for patients with FLT3-ITD acute myeloid leukaemia in first complete remission.
Topics: Adult; Aged; Antineoplastic Agents; Combined Modality Therapy; Female; fms-Like Tyrosine Kinase 3; Hematopoietic Stem Cell Transplantation; Humans; Leukemia, Myeloid, Acute; Maintenance Chemotherapy; Male; Middle Aged; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Remission Induction; Retrospective Studies; Sorafenib; Tandem Repeat Sequences; Transplantation Conditioning; Transplantation, Homologous; Treatment Outcome; Young Adult | 2016 |
[The efficacy of sorafenib to prevent relapse in patients with FLT3-ITD mutation positive acute myeloid leukemia after allogeneic hematopoietic stem cell transplantation].
Topics: Antineoplastic Agents; Combined Modality Therapy; Disease-Free Survival; Female; fms-Like Tyrosine Kinase 3; Hematopoietic Stem Cell Transplantation; Humans; Leukemia, Myeloid, Acute; Male; Mutation; Niacinamide; Phenylurea Compounds; Recurrence; Retrospective Studies; Secondary Prevention; Sorafenib; Survival Rate; Treatment Outcome | 2016 |
Sorafenib Therapy for Pediatric Acute Myeloid Leukemia with FMS-like Tyrosine Kinase 3-internal Tandem Duplication Mutations: 2 Case Reports.
Topics: Child; Child, Preschool; Drug Administration Schedule; Female; fms-Like Tyrosine Kinase 3; Hematopoietic Stem Cell Transplantation; Humans; Leukemia, Myeloid, Acute; Male; Mutation; Niacinamide; Phenylurea Compounds; Salvage Therapy; Sorafenib; Tandem Repeat Sequences; Treatment Outcome | 2017 |
Sorafenib-induced Thyroiditis in FMS-like Tyrosine Kinase 3-internal Tandem Duplication-mutated Acute Myeloid Leukemia.
Topics: Adult; Female; fms-Like Tyrosine Kinase 3; Humans; Leukemia, Myeloid, Acute; Mutation; Niacinamide; Phenylurea Compounds; Sorafenib; Tandem Repeat Sequences; Thyroiditis | 2016 |
Successful molecular targeted treatment of AML in pregnancy with Azacitidine and Sorafenib with no adverse fetal outcomes.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Azacitidine; Female; Humans; Leukemia, Myeloid, Acute; Molecular Targeted Therapy; Niacinamide; Phenylurea Compounds; Pregnancy; Pregnancy Complications, Neoplastic; Sorafenib; Treatment Outcome | 2018 |
Outcome of FLT3-ITD-positive acute myeloid leukemia: impact of allogeneic stem cell transplantation and tyrosine kinase inhibitor treatment.
Topics: Adult; Aged; Antineoplastic Agents; Disease-Free Survival; Female; fms-Like Tyrosine Kinase 3; Gene Duplication; Humans; Imidazoles; Induction Chemotherapy; Leukemia, Myeloid, Acute; Male; Middle Aged; Niacinamide; Phenylurea Compounds; Prognosis; Protein Kinase Inhibitors; Pyridazines; Retrospective Studies; Sorafenib; Stem Cell Transplantation; Transplantation, Homologous; Treatment Outcome; Young Adult | 2017 |
NT1721, a novel epidithiodiketopiperazine, exhibits potent in vitro and in vivo efficacy against acute myeloid leukemia.
Topics: Animals; Cell Line, Tumor; Cytarabine; DNA (Cytosine-5-)-Methyltransferase 1; Humans; Leukemia, Myeloid, Acute; Membrane Proteins; Mice; Niacinamide; Phenylurea Compounds; Piperazines; Polycomb Repressive Complex 1; Sorafenib | 2016 |
Treatment of Post-transplant Relapse of FLT3-ITD Mutated AML Using 5-Azacytidine and Sorafenib Bitherapy.
Topics: Antineoplastic Combined Chemotherapy Protocols; Azacitidine; fms-Like Tyrosine Kinase 3; Hematopoietic Stem Cell Transplantation; Humans; Leukemia, Myeloid, Acute; Mutation; Niacinamide; Phenylurea Compounds; Postoperative Care; Recurrence; Retreatment; Sorafenib; Treatment Outcome | 2017 |
Sorafenib (Nexavar) induces molecular remission and regression of extramedullary disease in a patient with FLT3-ITD+ acute myeloid leukemia.
Topics: Benzenesulfonates; fms-Like Tyrosine Kinase 3; Humans; Leukemia, Myeloid, Acute; Niacinamide; Phenylurea Compounds; Pyridines; Remission Induction; Sorafenib; Tandem Repeat Sequences | 2009 |
Complete resolution of leukemia cutis with sorafenib in an acute myeloid leukemia patient with FLT3-ITD mutation.
Topics: Aged; Antineoplastic Agents; Benzenesulfonates; fms-Like Tyrosine Kinase 3; Humans; Leukemia, Myeloid, Acute; Leukemic Infiltration; Male; Mutation; Niacinamide; Phenylurea Compounds; Pyridines; Skin; Sorafenib; Tandem Repeat Sequences; Treatment Outcome | 2009 |
FLT3-mutant allelic burden and clinical status are predictive of response to FLT3 inhibitors in AML.
Topics: Alleles; Antineoplastic Agents; Benzenesulfonates; Benzothiazoles; Carbazoles; Cell Death; Cell Line, Tumor; Drug Resistance, Neoplasm; fms-Like Tyrosine Kinase 3; Furans; Humans; Indazoles; Indoles; Leukemia, Myeloid, Acute; Mutation; Niacinamide; Phenylurea Compounds; Phosphorylation; Piperazines; Pyridines; Pyrroles; Sorafenib; Staurosporine; Sunitinib | 2010 |
A case of blast clearance on sorafenib in relapsed FLT3-ITD acute myeloid leukemia: evidence of efficacy continues to mount.
Topics: Antineoplastic Agents; Benzenesulfonates; Blast Crisis; fms-Like Tyrosine Kinase 3; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged; Niacinamide; Phenylurea Compounds; Point Mutation; Protein Kinase Inhibitors; Pyridines; Recurrence; Sorafenib | 2010 |
A pharmacodynamic study of sorafenib in patients with relapsed and refractory acute leukemias.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Benzenesulfonates; Extracellular Signal-Regulated MAP Kinases; Female; fms-Like Tyrosine Kinase 3; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged; Niacinamide; Phenylurea Compounds; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Protein Kinase Inhibitors; Pyridines; Recurrence; Sorafenib | 2010 |
Sorafenib induces sustained molecular remission in FLT3-ITD positive AML with relapse after second allogeneic stem cell transplantation without exacerbation of acute GVHD: a case report.
Topics: Adult; Antineoplastic Agents; Benzenesulfonates; Female; fms-Like Tyrosine Kinase 3; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; Humans; Leukemia, Myeloid, Acute; Niacinamide; Phenylurea Compounds; Point Mutation; Protein Kinase Inhibitors; Pyridines; Recurrence; Sorafenib; Transplantation, Homologous | 2010 |
Secondary resistance to sorafenib in two patients with acute myeloid leukemia (AML) harboring FLT3-ITD mutations.
Topics: Aged; Antineoplastic Agents; Benzenesulfonates; Drug Resistance, Neoplasm; Fatal Outcome; fms-Like Tyrosine Kinase 3; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged; Niacinamide; Phenylurea Compounds; Pyridines; Sorafenib | 2011 |
[Sorafenib in relapsed and refractory FLT3-ITD positive acute myeloid leukemia: a novel treatment option].
Topics: Adult; Aged; Antineoplastic Agents; Benzenesulfonates; Combined Modality Therapy; DNA Mutational Analysis; Dose-Response Relationship, Drug; Female; Hematopoietic Stem Cell Transplantation; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged; Niacinamide; Off-Label Use; Phenylurea Compounds; Pyridines; Remission Induction; Retreatment; Sorafenib | 2010 |
Sorafenib induces apoptosis in HL60 cells by inhibiting Src kinase-mediated STAT3 phosphorylation.
Topics: Apoptosis; Benzenesulfonates; Cell Cycle; Cell Growth Processes; Cell Line, Tumor; Cell Survival; DNA, Neoplasm; HL-60 Cells; Humans; Leukemia, Myeloid, Acute; Mitochondria; Myeloid Cell Leukemia Sequence 1 Protein; Niacinamide; Phenylurea Compounds; Phosphorylation; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-bcl-2; Pyridines; Sorafenib; src-Family Kinases; STAT3 Transcription Factor | 2011 |
Sorafenib treatment in 13 patients with acute myeloid leukemia and activating FLT3 mutations in combination with chemotherapy or as monotherapy.
Topics: Adult; Antineoplastic Agents; Benzenesulfonates; Enzyme Activation; Female; fms-Like Tyrosine Kinase 3; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged; Mutation; Niacinamide; Phenylurea Compounds; Pyridines; Retrospective Studies; Sorafenib; Treatment Outcome; Young Adult | 2010 |
Sorafenib for refractory FMS-like tyrosine kinase receptor-3 (FLT3/ITD+) acute myeloid leukemia after allogenic stem cell transplantation.
Topics: Adult; Antineoplastic Agents; Benzenesulfonates; Drug Resistance, Neoplasm; fms-Like Tyrosine Kinase 3; Gastrointestinal Diseases; Graft vs Host Disease; Humans; Inverted Repeat Sequences; Leukemia, Myeloid, Acute; Male; Middle Aged; Mutation; Niacinamide; Phenylurea Compounds; Pyridines; Salvage Therapy; Skin Diseases; Sorafenib; Stem Cell Transplantation; Tandem Repeat Sequences; Transplantation, Homologous; Young Adult | 2011 |
Marked bone marrow hypoplasia associated with sorafenib-induced marrow blast clearance in two patients with FLT3-ITD acute myeloid leukemia.
Topics: Aged; Antineoplastic Agents; Benzenesulfonates; Blast Crisis; Bone Marrow Diseases; fms-Like Tyrosine Kinase 3; Humans; Inverted Repeat Sequences; Leukemia, Myeloid, Acute; Male; Middle Aged; Mutation; Niacinamide; Phenylurea Compounds; Pyridines; Sorafenib; Tandem Repeat Sequences | 2011 |
FLT3 ligand impedes the efficacy of FLT3 inhibitors in vitro and in vivo.
Topics: Antineoplastic Agents; Benzenesulfonates; Carbazoles; Cells, Cultured; Drug Antagonism; fms-Like Tyrosine Kinase 3; Furans; Humans; Indazoles; Inhibitory Concentration 50; Leukemia, Myeloid, Acute; Membrane Proteins; Multicenter Studies as Topic; Niacinamide; Phenylurea Compounds; Piperazines; Protein Kinase Inhibitors; Pyridines; Randomized Controlled Trials as Topic; Sorafenib; Staurosporine; Treatment Outcome | 2011 |
Inhibition of eIF4E with ribavirin cooperates with common chemotherapies in primary acute myeloid leukemia specimens.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Benzenesulfonates; Binding, Competitive; Clinical Trials, Phase II as Topic; Cytarabine; Drug Synergism; Eukaryotic Initiation Factor-4E; Humans; Idarubicin; Leukemia, Myeloid, Acute; Leukemia, Myelomonocytic, Acute; Middle Aged; Niacinamide; Phenylurea Compounds; Pyridines; Ribavirin; RNA Caps; Sorafenib; Tumor Cells, Cultured; Tumor Stem Cell Assay | 2011 |
Activity of the multikinase inhibitor sorafenib in combination with cytarabine in acute myeloid leukemia.
Topics: Animals; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; ATP-Binding Cassette Transporters; Benzenesulfonates; Cell Line, Tumor; Cell Proliferation; Cell Survival; Chromatography, High Pressure Liquid; Confounding Factors, Epidemiologic; Cytarabine; Disease Models, Animal; Drug Administration Schedule; Gene Expression Regulation, Neoplastic; Humans; Interleukin Receptor Common gamma Subunit; Leukemia, Myeloid, Acute; Mice; Mice, Inbred NOD; Mice, SCID; Mitogen-Activated Protein Kinase 1; Mitogen-Activated Protein Kinase 3; Multidrug Resistance-Associated Proteins; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Pyridines; Signal Transduction; Sorafenib; Tandem Mass Spectrometry; Time Factors; Transplantation, Heterologous; Treatment Outcome | 2011 |
Treatment of FLT3-ITD-positive acute myeloid leukemia relapsing after allogeneic stem cell transplantation with sorafenib.
Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Benzenesulfonates; Combined Modality Therapy; Female; fms-Like Tyrosine Kinase 3; Hematopoietic Stem Cell Transplantation; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged; Niacinamide; Phenylurea Compounds; Prognosis; Protein Kinase Inhibitors; Pyridines; Recurrence; Retrospective Studies; Sorafenib; Transplantation, Homologous; Young Adult | 2011 |
Patterns of molecular response to and relapse after combination of sorafenib, idarubicin, and cytarabine in patients with FLT3 mutant acute myeloid leukemia.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Benzenesulfonates; Cytarabine; Female; fms-Like Tyrosine Kinase 3; Follow-Up Studies; Humans; Idarubicin; Leukemia, Myeloid, Acute; Male; Middle Aged; Mutation; Niacinamide; Phenylurea Compounds; Pyridines; Recurrence; Remission Induction; Sorafenib; Survival Rate | 2011 |
Donor erythrocytosis induced by sorafenib treatment after allogeneic hematopoietic SCT in a patient with acute myeloid leukemia.
Topics: Adult; Antineoplastic Agents; Benzenesulfonates; Hematopoietic Stem Cell Transplantation; Humans; Leukemia, Myeloid, Acute; Male; Niacinamide; Phenylurea Compounds; Polycythemia; Pyridines; Sorafenib; Transplantation, Homologous; Unrelated Donors | 2012 |
Sorafenib monotherapy gives sustainable suppression of FLT3 clone in untreated patients with FLT3-internal tandem duplication positive acute myeloid Leukaemia.
Topics: Aged; Aged, 80 and over; Antineoplastic Agents; Female; fms-Like Tyrosine Kinase 3; Humans; Leukemia, Myeloid, Acute; Male; Mutation; Niacinamide; Phenylurea Compounds; Sorafenib | 2012 |
Sorafenib as treatment for relapsed or refractory pediatric acute myelogenous leukemia.
Topics: Adolescent; Antineoplastic Agents; Benzenesulfonates; Child; Female; Humans; Leukemia, Myeloid, Acute; Male; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Pyridines; Recurrence; Remission Induction; Sorafenib | 2012 |
Survey and analysis of the efficacy and prescription pattern of sorafenib in patients with acute myeloid leukemia.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Benzenesulfonates; Data Collection; Female; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged; Niacinamide; Phenylurea Compounds; Practice Patterns, Physicians'; Pyridines; Remission Induction; Retrospective Studies; Sorafenib; Treatment Outcome; Young Adult | 2012 |
MCL1 down-regulation plays a critical role in mediating the higher anti-leukaemic activity of the multi-kinase inhibitor Sorafenib with respect to Dasatinib.
Topics: Antineoplastic Agents; Benzenesulfonates; Cell Line, Tumor; Dasatinib; Down-Regulation; Humans; Leukemia, Myeloid, Acute; Myeloid Cell Leukemia Sequence 1 Protein; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-bcl-2; Pyridines; Pyrimidines; Sorafenib; Thiazoles | 2012 |
Selective FLT3 inhibition of FLT3-ITD+ acute myeloid leukaemia resulting in secondary D835Y mutation: a model for emerging clinical resistance patterns.
Topics: Animals; Apoptosis; Aurora Kinases; Benzenesulfonates; Benzothiazoles; Blotting, Western; Cell Cycle; Cell Proliferation; Drug Resistance, Neoplasm; Female; fms-Like Tyrosine Kinase 3; Humans; Imidazoles; Leukemia, Myeloid, Acute; Mice; Mice, Nude; Mutation; Niacinamide; Phenylurea Compounds; Piperazines; Protein Kinase Inhibitors; Protein Serine-Threonine Kinases; Pyridines; Quinazolines; Sorafenib; Tandem Repeat Sequences; Tumor Cells, Cultured | 2012 |
Therapeutic potential of MEK inhibition in acute myelogenous leukemia: rationale for "vertical" and "lateral" combination strategies.
Topics: Antineoplastic Agents; Apoptosis; Benzamides; Benzenesulfonates; Cell Proliferation; Cell Survival; Diphenylamine; Drug Resistance, Neoplasm; Drug Synergism; Extracellular Signal-Regulated MAP Kinases; Humans; Inhibitory Concentration 50; Intracellular Signaling Peptides and Proteins; Leukemia, Myeloid, Acute; MAP Kinase Kinase 1; Niacinamide; Oligonucleotide Array Sequence Analysis; Phenylurea Compounds; Phosphorylation; Proto-Oncogene Proteins c-akt; Proto-Oncogene Proteins c-raf; Pyridines; Signal Transduction; Sorafenib; Transcriptome; Tumor Cells, Cultured | 2012 |
High activity of sorafenib in FLT3-ITD-positive acute myeloid leukemia synergizes with allo-immune effects to induce sustained responses.
Topics: Aged; Antineoplastic Agents; Benzenesulfonates; Female; fms-Like Tyrosine Kinase 3; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged; Niacinamide; Phenylurea Compounds; Pyridines; Retrospective Studies; Sorafenib | 2012 |
Use of Sorafenib as an effective treatment in an AML patient carrying a new point mutation affecting the Juxtamembrane domain of FLT3.
Topics: Aged; Amino Acid Sequence; Animals; Antineoplastic Agents; Benzenesulfonates; fms-Like Tyrosine Kinase 3; Humans; Leukemia, Myeloid, Acute; Male; Molecular Sequence Data; Niacinamide; Phenylurea Compounds; Point Mutation; Pyridines; Sequence Alignment; Sorafenib | 2012 |
Limitations of targeted therapy with sorafenib in elderly high-risk myelodysplastic syndrome and acute myeloid leukemia.
Topics: Female; Humans; Leukemia, Myeloid, Acute; Male; Myelodysplastic Syndromes; Niacinamide; Phenylurea Compounds; Sorafenib | 2013 |
Mechanisms of apoptosis induction by simultaneous inhibition of PI3K and FLT3-ITD in AML cells in the hypoxic bone marrow microenvironment.
Topics: Antineoplastic Agents; Apoptosis; Bone Marrow; Cell Hypoxia; Cellular Microenvironment; Coculture Techniques; Enzyme Inhibitors; fms-Like Tyrosine Kinase 3; Humans; Indazoles; Leukemia, Myeloid, Acute; Mutation; Myeloid Cell Leukemia Sequence 1 Protein; Niacinamide; Phenylurea Compounds; Phosphoinositide-3 Kinase Inhibitors; Proto-Oncogene Proteins c-akt; Proto-Oncogene Proteins c-bcl-2; Proto-Oncogene Proteins c-pim-1; Sorafenib; Stromal Cells; Sulfonamides | 2013 |
A novel combination therapy approach for the treatment of acute myeloid leukemia: the multi-kinase inhibitor sorafenib and the HDM2 inhibitor nutlin-3.
Topics: Antineoplastic Agents; Female; fms-Like Tyrosine Kinase 3; Humans; Imidazoles; Leukemia, Myeloid, Acute; Male; Niacinamide; Phenylurea Compounds; Piperazines; Sorafenib; Tumor Suppressor Protein p53 | 2012 |
Sorafenib is effective for imatinib-resistant FIP1L1/PDGFRA T674I mutation-positive acute myeloid leukemia with eosinophilia.
Topics: Antineoplastic Agents; Benzamides; Drug Resistance, Neoplasm; Humans; Imatinib Mesylate; Leukemia, Myeloid, Acute; mRNA Cleavage and Polyadenylation Factors; Mutation; Niacinamide; Phenylurea Compounds; Piperazines; Pyrimidines; Receptor, Platelet-Derived Growth Factor alpha; Sorafenib; Treatment Outcome | 2013 |
Sensitivity toward sorafenib and sunitinib varies between different activating and drug-resistant FLT3-ITD mutations.
Topics: Antineoplastic Agents; Benzenesulfonates; Cell Line, Tumor; Drug Resistance, Neoplasm; Drug Screening Assays, Antitumor; fms-Like Tyrosine Kinase 3; Humans; Indoles; Leukemia, Myeloid, Acute; Mutation; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Pyridines; Pyrroles; Sorafenib; Staurosporine; Sunitinib | 2007 |
Sorafenib induces apoptosis of AML cells via Bim-mediated activation of the intrinsic apoptotic pathway.
Topics: Apoptosis; Apoptosis Regulatory Proteins; Bcl-2-Like Protein 11; Benzenesulfonates; Cell Line; Drug Synergism; Humans; Leukemia, Myeloid, Acute; Membrane Proteins; Mitochondria; Niacinamide; Phenylurea Compounds; Proto-Oncogene Proteins; Pyridines; Signal Transduction; Sorafenib | 2008 |
Comparison of antitumor effects of multitargeted tyrosine kinase inhibitors in acute myelogenous leukemia.
Topics: Antineoplastic Agents; Apoptosis; Benzamides; Benzenesulfonates; Cell Cycle; Cell Line, Tumor; Cell Proliferation; Dose-Response Relationship, Drug; Drug Screening Assays, Antitumor; Humans; Imatinib Mesylate; Indoles; Leukemia, Myeloid, Acute; Niacinamide; Phenylurea Compounds; Piperazines; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Pyridines; Pyrimidines; Pyrroles; Sorafenib; Sunitinib | 2008 |